Polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium
A polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium-based medicament effectively treats arthritis and arthrosis by modulating the immune response, offering clinical improvement with minimal side effects, addressing the limitations of existing therapies.
Patent Information
- Application Number
- PCT/BR2026/050371
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-07-20
- Filing Date
- 2026-07-21
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for arthritis and arthrosis lack complete resolution, with existing therapies offering limited efficacy and significant adverse side effects, and there is a need for innovative therapies that can modulate the immune response effectively while minimizing immunosuppression and being economically viable.
The use of a polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium as an immunomodulator in a medicament formulation, administered weekly in therapeutically effective concentrations, to modulate the immune response and treat joint inflammation.
Demonstrates significant clinical improvement in arthritis and arthrosis with minimal adverse effects, as shown by experimental data in veterinary and human studies, providing pain relief and functional recovery without the harmful side effects associated with traditional treatments.
Smart Images

Figure IMGF000027_0001 
Figure IMGF000027_0002 
Figure IMGF000027_0003
Abstract
Description
POLYMERIC ANHYDRIDE OF MAGNESIUM PHOSPHOLINOLEATE- PALMITOLEATE AND PROTEIN AMMONIUM CROSS-REFERENCE TO RELATED APPLICATIONSThis application claims priority to and the benefit of Brazilian Patent Application No. BR 102026 018027-0, filed on July 20, 2026, and Brazilian Patent Application No. BR 102025 015313-0, filed on July 23, 2025. The entire contents of each of the foregoing Brazilian applications are hereby incorporated by reference in their entirety.BACKGROUND OF THE INVENTION FIELD OF THE INVENTION
[0001] The present disclosure relates to a polymeric anhydride of magnesium phospholinoleate-palmitoleate, and protein ammonium used for the manufacture of a medicament for the treatment of arthritis, in all its clinical manifestations, of arthrosis and other inflammatory joint diseases and comorbidities associated with these pathologies and with the treatments, affecting human beings and animals.
[0002] The present disclosure belongs to the field of veterinary and human medicine, being specifically related to a new practical application of the immunomodulator or biological response modifier chemically characterized as polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium, being used in an unprecedented manner for the manufacture of a medicament for the treatment of arthritis, in all its clinical manifestations, of arthrosis and other inflammatory joint diseases, and of the comorbidities associated with these pathologies, including adverse effects of therapies, affecting human beings and animals. The present disclosure also describes pharmaceutical compositions, and administration protocols using the present disclosure for the treatment of arthritis in all its clinical manifestations and of arthrosis affecting human beings and animals.DESCRIPTION OF RELATED ART
[0003] Arthritis in all its clinical presentations represents one of the main causes of functional disability and chronic pain worldwide, constituting a public health problem of increasing magnitude.
[0004] According to World Health Organization data, more than 350 million people globally suffer from some form of arthritis, in its various clinical manifestations, with the main one, that is, osteoarthritis, affecting approximately 240 million individuals in the world (Lancet Rheumatol 2023; 5 : e508-22). In the United States, it is estimated that 54 million adults have a medical diagnosis of osteoarthritis, representing 23% of the adult population (Zhang, Y and Jordan JM 2010).
[0005] The economic impact of arthritis in all its clinical manifestations is substantial, with direct and indirect costs estimated at more than 140 billion dollars annually just in the United States (Wang SX et al. 2014). These costs include direct medical expenses, loss of productivity, early retirement and costs associated with informal care. The prevalence of arthritis increases significantly with age, affecting 49.6% of adults aged 65 or older, becoming a growing concern with global population aging (Fallon EA et al. 2023).
[0006] Osteoarthritis or arthritis (OA) is characterized by presenting itself as an inflammatory process that affects lower and upper body joints, being a disease of a progressive nature, chronically affecting animals and human beings.
[0007] The main clinical signs include chronic pain, joint instability, stiffness and narrowing of the joint space, this last characteristic usually confirmed by radiography and other imaging examinations.
[0008] The disease results in a progressive loss of the structure and function of articular cartilage, especially in middle-aged and elderly patients. OA is considered one of the musculoskeletal diseases and one of the most frequent causes of disability.
[0009] Additionally, the economic costs of OA are high, due to its chronic character, including the costs related to the treatments and negative effects for the individualsand their families, forced to adapt their lives and homes to the disease, and finally the costs associated with the loss of productivity at work (Wang SX et al. 2014).
[0010] OA affects not only human beings, being also a common pathology in canines and felines that present bone and clinical alterations similar to human beings (FDA Report 2025).
[0011] OA constitutes a serious problem in veterinary medicine, especially in canines and felines. Statistical data show that up to 20% of dogs over one year of age present some degree of degenerative alterations in the joints; in cats over 12 years of age, this value approaches 90%. (FDA Report 2025), (MSD Veterinary Manual 2025 (Johnson KA et al -AVMA Pub).
[0012] Arthritis including its diverse clinical manifestations, as well as arthrosis, does not have until the present moment a complete resolution or definitive remission, with the treatments available in the prior art being limited mainly to the relief of symptoms, mainly of the associated pain conditions (Arthritis Foundation).
[0013] The main forms of arthritis are:
[0014] Osteoarthritis: Osteoarthritis, also known as osteoarthrosis, is a degenerative and chronic disease that causes the wear of the cartilage that lines the joints. This process results in pain, stiffness, limitation of movements and, in more advanced cases, bone alterations known as osteophytes.
[0015] Rheumatoid arthritis: autoimmune disease of a chronic nature causing inflammation in the joints, provoking pain, swelling, stiffness and loss of function in the more advanced stages of the disease.
[0016] Psoriatic arthritis: autoimmune disease of a chronic nature causing inflammation in the joints and associated with cutaneous psoriasis.
[0017] Septic arthritis: caused by inflammation in the joint associated with bacterial infection.
[0018] Gouty arthritis: caused by inflammation associated with the presence of uric acid in the joint.
[0019] Arthrosis: Arthrosis is a chronic degeneration involving cartilage or bone structure. In many cases the evolution of osteoarthritis leads to the appearance of arthrosis, with both pathologies then occurring in the same patient.
[0020] Pathophysiology of osteoarthritis, rheumatoid arthritis and psoriatic arthritis: Arthritis encompasses a heterogeneous group of conditions characterized by joint inflammation, with osteoarthritis, rheumatoid arthritis and psoriatic arthritis being the most prevalent forms. Osteoarthritis, traditionally considered a degenerative disease, is now recognized as a complex condition involving the entire joint, including cartilage, subchondral bone, synovial membrane, ligaments and periarticular muscles.
[0021] The pathogenesis of osteoarthritis involves an imbalance between anabolic and catabolic processes in the articular cartilage, mediated by pro-inflammatory cytokines such as interleukin- ip (IL- 1 P), tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) (Molnar V et al. 2021).
[0022] These cytokines stimulate the production of degradative enzymes, including matrix metalloproteinases (MMPs), resulting in the progressive degradation of the cartilaginous extracellular matrix (Molnar V et al 2021).
[0023] Rheumatoid arthritis, in turn, is characterized as being a systemic autoimmune disease characterized by chronic inflammation of the synovial membrane, leading to progressive joint destruction.
[0024] The pathogenesis involves aberrant activation of the immune system, with production of autoantibodies, formation of immune complexes and activation of autoreactive T and B subtype cells (Huang Q.Q & RM 2009).
[0025] Psoriatic arthritis, in turn, is characterized as a chronic and autoimmune inflammatory disease affecting a substantial number of people with psoriasis. It causes the immune system to attack healthy joints and skin, causing pain, swelling and stiffness.
[0026] Although there is no complete resolution in the prior art to date, early diagnosis and targeted treatments can prevent permanent joint damage (Deeb M and Maher L 2026).IMMUNOLOGICAL ASPECTS IN RHEUMATOID ARTHRITIS: ROLE OF CELLULAR RECEPTORS
[0027] Scientific advances in the prior art point to the fundamental role of the innate immune system in the pathogenesis of rheumatoid arthritis (RA). In rheumatoid arthritis, toll-like receptors (TLRs) are expressed by the cells of the joint. Furthermore, a variety of endogenous ligands of TLRs is present in the inflamed joints of patients with RA. Studies involving a variety of animal models suggest that TLR signaling is important in the pathogenesis of the disease. (Huang QQ & Pope RM 2009).
[0028] In general terms, data from the state of the art suggest that activation by endogenous ligands of TLRs can contribute to the persistent expression of pro-inflammatory cytokines by macrophages and to the joint lesion of the cartilage and bone that occur in rheumatoid arthritis (RA).
[0029] Consequently, these data indicate the potential for the suppression or blockade of TLR signaling as an innovative therapeutic approach in patients with RA (Huang QQ & Pope RM 2009).PRIOR ART: TREATMENTS
[0030] In the prior art there is still no complete resolution for arthritis in its diverse forms, and early treatments, including medicaments, lifestyle changes, supportive treatments and finally surgery can reduce the risk of lesions in the joints and limit the impact of the disease (John Hopkins Arthritis Center).
[0031] These treatments as a whole aim to reduce inflammation in the joints, relieve pain, prevent or delay lesions in the joints, reduce the degree of disability and thus allow the patient to be as active as possible (Arthritis Foundation) and (John Hopkins Arthritis Center).
[0032] In the prior art, there are available 06 (six) general classes of medicaments or non-pharmacological therapies used in the treatment of arthritis in all its clinical presentations and also of arthrosis (Arthritis Foundation) and (John Hopkins Arthritis Center): (1) Non-steroidal anti-inflammatory drugs (NSAIDs), (2) Corticosteroids, (3) Disease-modifying antirheumatic drugs (DMARDs), (4) Biological treatments (including TNF-alpha inhibitors), (5) Opioid or opiate analgesics, (6) Surgery.
[0033] For purely illustrative purposes in this specification, some of the main medicaments available in the state of the art and their limitations are listed below, without intending, however, to offer an exhaustive list or limit the scope of the present disclosure (Arthritis Foundation):DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs)
[0034] Disease-modifying antirheumatic drugs have their mechanism of action related to the blockade of the effects of the products released when the immune system attacks the joints, which, otherwise, could cause even more damage to the nearby bones, tendons, ligaments and cartilages. The most used biological response modifying medicaments include:
[0035] Methotrexate (IUPAC: (S)-2-(4-(((2,4-diaminopteridin-6-yl) methyl) methylamino) benzamido) pentanedioic acid) CAS: 59-05-2): Methotrexate is normally the first medicament administered for rheumatoid arthritis. It can be associated with another biological response modifier and also with steroids (corticosteroids).
[0036] Adverse effects: The most frequent adverse side effects can include nausea, loss of appetite, pain in the mouth region, diarrhea, headache, alopecia, disturbances in the hematopoietic system and liver.
[0037] Leflunomide (IUPAC: 5-methyl-N-[4-(trifluoromethyl)phenyl]-l,2-oxazole-4-carboxamide) CAS: 75706-12-6. Leflunomide is a pyrimidine synthesis inhibitor. It is used to treat active, moderate to severe rheumatoid arthritis, and active psoriatic arthritis, acting by reducing the activity of the immune system, with animmunosuppressive and anti-inflammatory effect. It reduces the symptoms and delays the destruction of the joints, presenting efficacy similar to that of methotrexate in terms of signs and symptoms, which makes it a viable alternative for patients who have failed or are intolerant to methotrexate.
[0038] Adverse effects: The most frequent adverse side effects can include diarrhea, elevation of liver enzymes, alopecia, skin rash, allergic reaction, asthenia, abdominal pain, hypertension. The elevations of liver transaminases reversed with the interruption of the medicament in clinical trials. As leflunomide and its metabolites are teratogenic, its use is prohibited in pregnant women or those suspected of being pregnant.
[0039] Hydroxychloroquine (IUPAC: 2-[{4-[(7-Chloro-4-quinolinyl) amino] pentyl} (ethyl) amino] ethanol) CAS: 747-36-4
[0040] Hydroxychloroquine was developed from chloroquine, which was used for the treatment of malaria, but presenting lower toxicity than the original substance.
[0041] Hydroxychloroquine is an established medicament for the treatment of rheumatoid arthritis (RA). It can be used in association with one or two other diseasemodifying antirheumatic drugs, mainly methotrexate.
[0042] Adverse effects: The most frequent adverse side effects can include anorexia, headache, skin reactions, visual alterations, abdominal pains, diarrhea, vomiting, blood disturbances, and increased risk of hypoglycemia episodes in patients with diabetes.
[0043] Sulfasalazine (IUPAC: 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-l-yl]benzoic acid) CAS: 599-79-1 : It belongs to a group of medicaments called aminosalicylates. These medicaments help to reduce inflammation and can help with tissue healing.
[0044] Adverse effects: The most frequent adverse side effects can include indigestion, feeling of nausea.
[0045] Biological treatments: Biological medicaments have their mechanism of action related to the blockade or neutralization of activating substances of the immune system responsible for the attack on the joints, leading to the development of arthritis in all its clinical manifestations and of arthrosis.
[0046] Usually administered by injection, biological medicaments are the most recent acquisitions for the treatment of rheumatoid arthritis in the prior art.
[0047] Tumor Necrosis Factor Alpha (TNF-ALPHA) Inhibitors: Tumor necrosis factor alpha (TNF) is a pro-inflammatory cytokine produced by macrophages and lymphocytes. It is found in large quantities in the rheumatoid joint and is produced locally in the joint by synovial macrophages and lymphocytes that infiltrate the synovium of the joint (CAMPBEL, Jamie et al. 2011).
[0048] TNF antagonists were the first biological medicaments to be approved for the treatment of rheumatoid arthritis (RA).
[0049] There are currently some TNF inhibitors approved by the American regulatory agency (FDA) for the treatment of RA: Etanercept, Infliximab, Adalimumab, Certolizumab pegol and Golimumab.
[0050] However, about a third of individuals do not respond to these emerging therapeutics, and this class of medicaments still presents severe adverse side effects.
[0051] We present below some of them, which are representative of this class of medicaments (CAMPBEL, Jamie et al 2011), (Arthritis Foundation) and (John Hopkins Arthritis Center).
[0052] Adalimumab: Monoclonal antibody used by injection that has as a therapeutic target the blockade of the TNF-alpha molecule, directly involved in the pathogenesis of several autoimmune conditions in the field of rheumatology. It is approved for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and psoriasis, among other diseases.
[0053] Adverse side effects: allergy, mood swings, anxiety, insomnia, headaches, conjunctivitis, swelling of the eyes, dizziness, hypertension, cough, shortness of breath, nausea, abdominal pain and redness at the application site.
[0054] Etanercept: Indicated for reducing the signs and symptoms and inhibiting the progression of structural damage in patients with rheumatoid arthritis. Etanercept is indicated in the treatment of moderate to severe arthritis, when the response to one or more disease-modifying antirheumatic drugs - DMARDs - proves unsatisfactory. It is also indicated for the treatment of psoriasis including psoriatic arthritis.
[0055] Contraindications: Contraindicated for patients with severe active infections, including chronic or localized infections.
[0056] Most common adverse side effects: Presence of septicemia or risk to develop septicemia, reactions at the administration site including:
[0057] Severe infections by bacteria, mycobacteria (including tuberculosis), viruses and fungi.
[0058] Opportunistic infections including invasive fungal infection, parasitic (including protozoa), viral (including herpes zoster), bacterial (including Listeria and Legionella) and atypical mycobacterial infections.
[0059] Opioids or Opiates: Opiates are a class of natural, semi-synthetic and synthetic drugs including both medicaments obtained through medical prescription, and illegal drugs such as heroin. Drugs used legally, such as hydrocodone, oxycodone, morphine, codeine, fentanyl and others, are used mainly for the treatment of pain.
[0060] However, just like illegal opiates, prescription opiates can cause dependence. Although widely used and presenting limited efficacy in the treatment of pain associated with arthritis and arthrosis, this class of medicaments, on the other hand, presents a high degree of risk for abuse and dependence in patients.
[0061] Examples: Morphine, heroin, codeine, oxycodone and fentanyl.
[0062] A study conducted in the USA showed that chronic consumption of opiates increased from 7.4% in 2002 to 16.9% in 2015 in people with rheumatoid arthritis (Schnitzer TJ et al. 2023), (Singh JA and Cleveland JD 2021).SUMMARY OF THE PRIOR ART: LIMITATIONS OF TREATMENTS
[0063] In summary, it becomes evident that in the present prior art of Medicine, inflammatory joint diseases, notably arthritis in all its clinical manifestations and arthrosis as well as the associated morbid states, up to the present moment, have no possibility of complete resolution.
[0064] All these modalities cited above present limitations, whether in terms of efficacy, or due to the emergence of adverse side effects or even those preventing their continuity.
[0065] Clearly in the prior art, there is room for new treatments and improvements aiming to increase efficacy and reduce the undesired side effects associated with treatments.BRIEF SUMMARY OF THE INVENTION
[0066] The present disclosure, that is, the use of a polymeric (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) now being used in an unprecedented manner for the manufacture of medicaments for the treatment of arthritis in all its clinical manifestations and of arthrosis, fills important gaps in the state of the art, contrasting strongly with the medicaments available in the prior art.
[0067] Because it presents effectiveness with minimal adverse effects associated with its use, as will be explained in detail in this specification.
[0068] The present disclosure was also tested in practice and produced robust experimental data obtained in a veterinary clinical study with groups of dogs suffering from spontaneous arthritis and arthrosis and clinical study with human patients suffering from rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
[0069] The results demonstrated significant clinical improvement evaluated by pain questionnaires, widely accepted in the state of the art of Medicine for this purpose(Canine Brief Pain Inventory for dogs and Brief Pain Inventory and SF 36 Questionnaire for humans, without measurable and / or harmful side effects).
[0070] The pharmaceutical composition comprises the immunomodulator as an active ingredient in therapeutically effective concentrations, establishing a safe and effective dosage protocol for modulation of the immune response and treatment of joint inflammation. Specifically, the composition comprises the compound polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium and a pharmaceutically acceptable excipient.
[0071] In a preferred embodiment, the excipient is sterile 0.9% sodium chloride or even a combination of sodium chloride, dibasic sodium phosphate, monobasic sodium phosphate, water for injection and physiological saline (0.9% NaCl).
[0072] The composition can be administered orally or injectably, with the injectable formulation being applied subcutaneously or intramuscularly, preferably once a week. The administered amount varies from 10 to 40 mg, preferably 25 mg.
[0073] The present disclosure in the form of a medicament has broad applicability in the treatment of various forms of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis and other joint inflammatory conditions, including arthrosis.
[0074] The medicament made available by the present disclosure can be used as monotherapy or in combination with other therapeutic agents, or even in their substitution, offering flexibility in the treatment and clinical management of arthritis, in all its clinical manifestations or forms and of arthrosis.
[0075] The present disclosure is particularly valuable for all human and animal patients of all ages suffering from arthritis in all its forms, in the short and long term and also from arthrosis.
[0076] And finally as a substitution therapy for those who do not respond adequately to conventional treatments, patients with contraindications to traditional antiinflammatories, and patients who develop unacceptable side effects with existingtherapies. In a preferred embodiment, the present disclosure is used in substitution for DMARDS, such as methotrexate, for non-steroidal medicaments, such as meloxicam, and for non-steroidal opioid medicaments, such as fentail, codeine and oxycodone.
[0077] Additionally, the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium comprises 11.6 ± 4.0% of total lipids, being 22.7 ± 5.0% of palmitoleic acid, 42.9 ± 2.0% of linoleic acid, and 32.0 ± 3.0% of oxidized linoleic acid, 20.1 ± 0.9% of magnesium ions, 10.0 ± 3.3% of ammonium ions, 45.2 ± 2.7% of phosphate, and 0.49 ± 0.01% of protein, where the protein portion comprises Asp 7.19%, Thr 3.56%, Ser 7.56%, Glu 8.53%, Pro 0.5%, Gly 9.69%, Ala 7.46%, Vai 1.0%, Met 4.38%, He 2.54%, Leu 3.03%, Tyr 0.5%, Phe 1.0%, His 2.83%, Lys 3.56%, Trp 1.3%, and Arg 35.2%.
[0078] In veterinary medicine, the present disclosure offers a safe alternative for the short and long-term treatment of arthritis in all its forms and of arthrosis in animals of all ages or with comorbidities
[0079] It may also finally be used as a substitution therapy for those who do not respond adequately to conventional treatments, patients with contraindications to traditional anti-inflammatories, and patients who develop unacceptable side effects with existing therapies.
[0080] This new practical application or utility of the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) is now used for the manufacture of medicaments for the treatment of arthritis, in all its clinical manifestations, and of arthrosis.DETAILED DESCRIPTION OF THE INVENTION
[0081] The present disclosure, as will be explained in detail in this application, cannot or could not in any way be visualized or projected by a person of ordinary skill in the art from prior knowledge, isolated or combined with each other, or even referring to the compound (polymeric anhydride of magnesium phospholinoleate-palmitoleateand protein ammonium) that is used in the present disclosure for the manufacture of medicaments, by the arguments described below.THE PRESENT DISCLOSURE: BACKGROUND IN THE PRIOR ART
[0082] It is reported in the prior art that the immunomodulatory compound named polymeric anhydride of magnesium phospholinoleate-palmitoleate, and protein ammonium is capable of exerting therapeutic activity in neoplasms and in some infectious diseases (PI 0801803-0; US 8.889.153 B2; US 9.295.682 B2; EP 2259799 Bl).
[0083] Recently, this compound was used in the treatment of experimental infection of animals contaminated with Schistosoma spp, a parasitosis that affects the liver leading to progressive organ failure, among other complications.
[0084] These problems and complications are caused by the parasite eggs lodged in the liver, which in turn cause an inflammatory reaction of the host organism, with the formation of reactive tissue called hepatic granulomas (Silva JCS et al. 2021).
[0085] In these experiments, the compound not only acted against the disease-causing parasite, but also acted preventively in the formation of hepatic granulomas.THE PRESENT DISCLOSURE
[0086] Starting from this effect in this parasitosis, that is, schistosomiasis, with preventive action in the formation of hepatic granulomas, the immunomodulator was then directed to treat canines with visceral leishmaniasis, another severe parasitosis that affects animals and human beings.
[0087] It should be noted that the immunomodulator acts therapeutically in this mentioned parasitosis, that is, visceral leishmaniasis, which is well established in the prior art (Santiago MEB et al. 2013).
[0088] This severe parasitosis, where the domestic dog is considered the main reservoir for the causative agent - Leishmania chagasi - presents inflammatory reactions in the hepatic tissue caused by the presence of the parasite in the organism,also with the formation of granulomas in this organ (Sant’ Ana JAP et al. 2007) and (Salguero FJ et al 2018).EXPERIMENTAL DESIGN
[0089] Therefore, to treat this parasitosis, 10 animals - canines of different ages - all carriers of visceral leishmaniasis confirmed by PCR examinations, were selected for the use of the immunomodulator polymeric (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium).
[0090] Of these 10 animals, 4 were also affected by bone malformation characteristic of the presence of arthritis and arthrosis and associated inflammation, events confirmed by X-ray and Ultrasonography examinations.
[0091] As the most evident clinical manifestation of arthritis and arthrosis, these 4 (four) animals presented difficulty in locomotion, difficulty in standing in an erect posture from a sitting or lying position, and inability to climb steps and ramps.
[0092] And they also showed signs of pain manifested by vocalization when subjected to pressure or manipulation of the parts affected by arthritis. In this case, arthritis and arthrosis were possibly associated with the advanced age of the treated dogs, which was in the range of 14-15 years.
[0093] All animals were subjected to the application of the immunomodulator at a weekly dosage of 1 mg / kg of body weight formulated in physiological saline (0.9% NaCl) administered subcutaneously, with a duration of 1 week.
[0094] Surprisingly, the 4 animals with arthritis and arthrosis showed clinical signs of response for the improvement of the sequelae or symptoms of arthritis and arthrosis, although very discrete.
[0095] This clinical response manifests itself in the form of a small recovery of the ability to place oneself in an erect posture from a lying or sitting position.
[0096] In the other animals of the experiment, that is, in the dogs without arthritis and arthrosis, no effect was visualized on the locomotion capacity, whether an increase ordecrease, further indicating in a preliminary manner that the unexpected effect of the use of the immunomodulator was in fact linked to the adverse clinical manifestations of arthritis and arthrosis, that is, pain and greatly diminished locomotion capacity.
[0097] This effect was absolutely unexpected, since the improvement of the joint manifestations observed does not stem directly from the parasitic mechanism of visceral leishmaniasis nor from the elimination of the causative agent. Indeed, the animals in the experiment without arthritis and arthrosis did not present any alteration in locomotor capacity, which indicates that the observed effect is attributable to an action of the immunomodulator on the joint inflammatory process, and not to an indirect consequence of the treatment of parasitosis.
[0098] Furthermore, it is known in the prior art (Favaro WJ et al 2012) that the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) has its mechanism of action linked to the stimulation of cellular receptors of the toll-like receptor (TLR) type, more precisely cellular receptors of type 2 (TLR2) and 4 (TLR4).
[0099] And it is proven in the prior art that the presence of TLR (toll-like receptor) type receptors in the moving parts of the locomotor system (joints, knees, cartilages for example) are factors that stimulate the inflammatory response of the organism, leading to the triggering and maintenance of arthritis and arthrosis and its pathological consequences (Huang QQ & Pope RM 2009).
[0100] In this scenario, a compound capable of activating TLR-type receptors (Favaro WJ et al. 2012) such as the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) to be used for the manufacture of a medicament for treatments of arthritis in all its clinical manifestations and of arthrosis and its comorbidities, which is the object of the present disclosure, would be generally contraindicated to be used in the manufacture of medicaments to be used for these pathologies cited above.
[0101] Clearly, no person of ordinary skill in the art of Medicine would propose or even be able to visualize or project the use of a medicament containing this active ingredient (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) in these pathologies, using the data published in the prior art, whether in an isolated manner or even combined with each other.
[0102] Undoubtedly, the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium), being an activator of TLR-type cellular receptors as is well established in the prior art (Favaro WJ et al. 2012), would never have the conditions to be used as an active ingredient or component in the manufacture of new medicaments for the treatment of joint diseases, including arthritis in all its forms and of arthrosis (Huang QQ & Pope RM 2009).
[0103] Since the present disclosure would undoubtedly be visualized as an element capable of aggravating for the worse the health condition of the patients as well as would negatively affect their quality of life, already compromised by the cited pathologies.MECHANISM OF ACTION OF THE PRESENT DISCLOSURE: IMMUNOLOGICAL TOLERANCE
[0104] It should be clarified, for purposes of enablement, the possible mechanism by which an agonist of TLR2 and TLR4 receptors — pro-inflammatory and, therefore, contraindicated in articular inflammatory diseases — can produce, in a surprising manner, clinical improvement in arthritis and in arthrosis by acting on the underlying inflammatory process.
[0105] Without the present disclosure being in any way limited to the theory set forth below, the inventor proposes that the observed therapeutic effect stems from the phenomenon of immunological tolerance described in the prior art of immunology (Medvedev AE et al 2020), (Collins PE et al. 2015, Butcher SK et al. 2018).
[0106] Indeed, it is established that the initial and acute stimulation of TLR2 and TLR4 receptors triggers a pro-inflammatory response, with the release of cytokinessuch as I -ip, TNF-a, and IL-6. However, the repeated, controlled, and sustained stimulation of these same receptors — such as occurs in the weekly administration protocol of the active principle of the present disclosure — induces a state of cellular hyporesponsiveness, in which the cell ceases to respond in a pro -inflammatory manner to subsequent stimuli from the same ligand or from correlated ligands. (Medvedev AE et al. 2020), (Collins PE et al 2015, Butcher SK et al. 2018).
[0107] This state of tolerance is mediated by the transcriptional reprogramming of innate immunity cells, notably of synovial macrophages, with negative regulation of the signaling pathways dependent on MyD88 and NF-KB, induction of intracellular negative regulators, and shift of the cellular secretion profile towards cytokines of a regulatory and anti-inflammatory profile. (Medvedev AE et al. 2020), (Collins PE et al 2015, Butcher SK et al. 2018).
[0108] In the joints affected by arthritis and by arthrosis, where endogenous TLR ligands are admittedly abundant and sustain the persistent expression of pro-inflammatory cytokines by macrophages, the installation of this state of tolerance (Medvedev AE et al. 2020, Collins PE et al. 2015, Butcher SK et al. 2018) possibly induced by the repeated introduction of the present disclosure into the organism of the animal or human interrupts the cycle of self-sustained chronic inflammation, resulting in the reduction of the local inflammatory response, in the regression of the joint effusion, and in the consequent relief of pain and functional recovery — exactly the condition documented experimentally in this specification, both in the canine model and in human patients.
[0109] For it is sufficiently explained in the prior art that the present disclosure is a ligand for TLR 2 and TLR 4 (Favaro WJ et al 2012) and possibly its repeated introduction into the organism may be inducing a state of tolerance (Medvedev AE et al. 2020, Collins PE et al 2015, Butcher SK et al. 2018) that suppresses or obstructs the inflammatory response in arthritis and arthrosis.
[0110] It is precisely this inversion of the expected direction of the response — from pro-inflammatory to tolerogenic — (Medvedev AE et al 2020, Collins PE et al. 2015) that is possibly responsible for the unexpected and non-obvious therapeutic effect of the present disclosure, which could not be anticipated by a person of ordinary skill in the art from the knowledge that the compound is an agonist of TLR2 and TLR4 (Favaro WJ et al. 2012), considered isolatedly or in combination with the other documents of the prior art.[oni] This conceptual leap would be impossible or unfeasible even for the person of ordinary skill in the art starting from the existing information in the prior art for the active ingredient of the present disclosure (Favaro WJ et al. 2012) to be able to visualize or create the present disclosure in whole or in part.
[0112] It should be noted that the hypothesis of the mechanism of action for the present disclosure set forth herein is presented merely for illustrative purposes, not constituting a limitation to the scope of the present disclosure, whose practical efficacy is sufficiently demonstrated by the experimental data presented in this specification, regardless of the theory or hypothesis that explains it.
[0113] In conclusion, the visualization or translation of the use of an articular, that is, of Toll-like cellular receptors (TLR2 and TLR 4), that is, of the active ingredient of the present disclosure polymeric (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) as a component or active ingredient to be used for the manufacture of medicaments for the treatment of joint disease, that is, of arthritis in its various forms and of arthrosis, which in the prior art was used for the treatment of infectious disease, from the existing knowledge (PI 0801803-0; US 8,889,153 B2; US 9,295,682 B2; EP 2259799 Bl) and still other publications, would be unfeasible if used isolatedly or in a combined manner even for the most well-endowed person of ordinary skill in the art.LIMITATIONS OF CURRENT TREATMENTS - PRIOR ART
[0114] The treatments currently available for arthritis include a variety of pharmacological and non-pharmacological approaches, each with specific limitations that restrict in practice their efficacy and clinical applicability.
[0115] Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Although effective for controlling pain and inflammation, NSAIDs are associated with significant cardiovascular, gastrointestinal, and renal risks. Prolonged use can result in peptic ulcers, gastrointestinal bleeding, hypertension, heart failure, and renal dysfunction. Epidemiological studies demonstrate that the risk of severe cardiovascular events increases by 10-50% with the regular use of NSAIDs.
[0116] Corticosteroids: Although potent anti-inflammatories, corticosteroids cause severe systemic side effects with prolonged use, including suppression of the hypothalamic-pituitary-adrenal axis, osteoporosis, diabetes mellitus, hypertension, cataracts, glaucoma, and increased susceptibility to infections. These effects significantly limit their long-term use.
[0117] Biological Therapies: Medicaments such as TNF-a inhibitors, although revolutionary in the treatment of rheumatoid arthritis, present important limitations. They are extremely expensive, with annual costs frequently exceeding thousands of dollars per patient. Furthermore, they cause significant immunosuppression, increasing the risk of severe infections, including tuberculosis and invasive fungal infections. Approximately 30-40% of patients do not respond adequately to these therapies.
[0118] Opioid Analgesics: The use of opioids for chronic joint pain is strongly associated with risks of dependence, tolerance, and side effects such as sedation, constipation, and respiratory depression. The opioid crisis in the United States, considered a public health emergency, highlighted the dangers of the prolonged use of these medicaments and their devastating consequences on the lives of those affected by dependence.
[0119] Surgical methods: The use of surgery for arthritis and arthrosis is considered the last resort of treatment, indicated only when conservative treatments -physiotherapy, weight loss, and medicaments - fail.
[0120] The objectives are to relieve chronic pain and restore mobility, using different techniques according to the severity of the disease and the affected joint. The main surgical interventions include:
[0121] Arthroplasty: It is the replacement of the damaged joint with artificial components (metallic or polyethylene). It can restore mobility and drastically reduce pain.
[0122] Arthroscopy: Minimally invasive procedure used in specific cases for the joint, to remove loose fragments or correct mechanical problems, although its use in the treatment of arthrosis is today more cautious.
[0123] Osteotomy: Procedure that alters the alignment of the bones to transfer the load from the worn compartment to a healthier area. It is frequently indicated for younger patients.
[0124] Arthrodesis: Consists of fusing the bones of the joint. Although it eliminates the movement of that specific region, it guarantees stability and pain relief.NEED FOR THERAPEUTIC INNOVATION
[0125] Despite significant advances in the understanding of the pathophysiology of arthritis and of arthrosis for the development of new therapies, important gaps remain in the therapeutic arsenal available for both human beings and animals, including:
[0126] Scarcity of Disease-Modifying Therapies: Most available treatments offer symptomatic relief without significantly modifying the progression of the underlying disease.
[0127] Limiting Safety Profiles: Many therapies are associated with adverse side effects that limit their continued or prolonged use.
[0128] Variable Therapeutic Response: A significant proportion of patients does not respond adequately to available treatments, High Costs:
[0129] High costs: Many of the recently developed biological therapies are frequently inaccessible to patients due to high costs.
[0130] Dosing Complexity: Many therapeutic regimens require frequent administration or intensive monitoring, for the detection of adverse effects and opportunistic infections.
[0131] Clearly, there is an urgent medical need unmet or poorly met in the prior art, for innovative therapies that can provide effective pain relief and act on joint inflammation with a safety profile superior to currently available treatments.
[0132] Hypothetically, such therapies should be able to provide or have the following characteristics:— Modulate the immune response in a balanced manner, promoting resolution of inflammation without causing excessive immunosuppression. — Present efficacy comparable or superior to existing treatments.— Demonstrate an adequate safety profile aiming at prolonged use.— Be economically viable and accessible to patients.— Offer ease of use aiming at better patient adherence to therapy.THE INNOVATION AS A THERAPEUTIC ALTERNATIVE
[0133] Taking into account the existing flaws in the prior art for the treatment of arthritis in all its clinical forms and of arthrosis, the present disclosure fills gaps in the prior art through the provision of a biological response-modifying therapy using the compound polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium as an active principle for the manufacture of new medicaments for these cited pathologies.
[0134] The steps of the inventive activity to create the present disclosure are described below:THE CONSTRUCTION OF THE PRESENT DISCLOSURE-INVENTIVE ACTIVITY
[0135] Starting from the more than limited effect observed in some animals carrying visceral leishmaniasis that showed action in a pathology suggestive of associated joint inflammatory disease (arthritis and / or arthrosis) combined with the data of protective effect in the liver in animals with parasitosis (schistosomiasis), the present disclosure was visualized and constructed as an emerging novelty in the prior art for use in totally distinct pathologies.
[0136] These were the steps followed regarding the inventive activity that allowed the creation of the new medicament.
[0137] Now to allow in an unprecedented manner its use in inflammation underlying the pathological conditions of arthritis and arthrosis and by this route assist in their treatment and in the elimination or minimization of their symptoms.
[0138] For this innovative purpose, it was formulated as an injectable medicament to be used in the treatment of joint diseases and with a better safety profile in relation to the current prior art accompanied by maximized utilization protocols to improve patient adherence to the treatment.
[0139] After its inventive conception, the new medicament was tested and used in a practical manner for verification of its effectiveness and safety in established animal models for the study of articular inflammatory pathologies and then in human beings as described below:ANIMAL MODELS FOR THE STUDY OF INFLAMMATORY DISEASES
[0140] The development and testing of effective therapies for human arthritis critically depends on the availability of animal models that reproduce as faithfully as possible the pathophysiology of the human disease.
[0141] Among the various available models, the canine model of spontaneous arthritis is widely recognized as one of the most representative of the human condition (Sharun K et al. 2025).
[0142] Dogs naturally develop osteoarthritis with histopathological, radiographic, biochemical, and clinical characteristics notably similar to those observed in humans. This similarity includes:
[0143] Anatomical Characteristics: The canine articular anatomy is sufficiently similar to the human to allow relevant extrapolation of experimental data.
[0144] Disease Progression: Canine osteoarthritis progresses in a manner similar to the human, with gradual development of cartilaginous alterations, formation of osteophytes, and subchondral sclerosis.
[0145] Inflammatory Response: The inflammatory mediators involved in canine arthritis are homologous to the human ones, including cytokines, chemokines, and degradative enzymes.INSTRUMENTS — CANINE BRIEF PAIN INVENTORY
[0146] The objective evaluation of the therapeutic efficacy in animal models for the study of arthritis requires validated and reliable measurement instruments.
[0147] The Canine Brief Pain Inventory (CBPI) is presented in the form of a questionnaire to be filled out by the person responsible for the animal representing the gold standard for the evaluation of pain and joint function in dogs, having been specifically developed and validated for this purpose (Brown DC et al. 2008).
[0148] The CBPI was adapted from the human Brief Pain Inventory (BPI), an instrument widely used and validated for the evaluation of pain in human patients.
[0149] This direct correspondence between pain evaluation instruments linked to joint inflammations such as arthritis and arthrosis in canines and humans facilitates the translation of experimental data for clinical application.PRACTICAL EXAMPLE OF THE PRESENT DISCLOSURE — DOGS WITH CHRONIC ARTHRITIS
[0150] An experiment to evaluate the practical use of the present disclosure was conducted, using forty-two (42) dogs (named CPI to CP42) between April 2024 andMay 2025, using diverse breeds with a confirmed diagnosis of spontaneous arthritis as a translational model for human arthritis.
[0151] These animals were evaluated through Canine Brief Pain Inventory (CBPI) questionnaires.
[0152] Complete individual blood and biochemical tests were performed throughout the entire experiment for the evaluation of possible adverse systemic effects. Radiographic and ultrasound examinations were also performed throughout the experiment.
[0153] The results are presented below in this specification, but without at any time intending in any way to limit the utility or scope of the present disclosure.EXPERIMENTAL DESIGN
[0154] Prospective, controlled study, with longitudinal evaluation of dogs with spontaneous arthritis treated with the compound of the present disclosure following the dosage protocol of the present disclosure (25 mg per week formulated and suspended in 0.9% physiological saline for 4 to 7 consecutive weeks).
[0155] Selection Criteria: The animals were selected based on rigorous criteria including:— Age greater than 1 (one) year— Confirmed radiographic diagnosis of arthritis with characteristic alterations.— Evident and persistent lameness for at least 3 months— Stratification of pain intensity by the Canine Brief Pain Inventory (CBPI) in the baseline evaluation, without establishment of a minimum eligibility threshold— Absence of other significant medical conditions— Informed consent of the owners
[0156] Treatment Protocol: Each animal received 25 mg of the compound of the present disclosure subcutaneously, once a week, for 4 to 7 consecutive weeks. The fixed dose of 25 mg was established based on previous studies that demonstrated therapeutic efficacy in this dosage range and on preclinical safety data, being administered uniformly to all animals, regardless of individual body weight.
[0157] Evaluations Performed:
[0158] Evaluation mode: - Canine Brief Pain Inventory (CBPI) applied weekly by the owners and veterinarians
[0159] Inclusion criteria: The inclusion criteria contemplated animals with a confirmed diagnosis of arthritis or arthrosis, by clinical examination, animal history, and imaging examinations, age greater than one-year, stable weight during the observation period, and absence of other clinical conditions that could interfere with the pain evaluation.
[0160] Exclusion criteria: Animals with a history of adverse reactions to immunomodulators, pregnant or lactating females, and patients with significant comorbidities that could compromise the safety of the treatment were excluded.
[0161] Treatment Protocol: The established therapeutic protocol consisted of the weekly administration of a dose of 25mg of polymeric (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) subcutaneously, with a duration of 4 (four) to 7 (seven) weeks, according to the clinical evolution of each animal.
[0162] This active ingredient was formulated as a medicament in suspension 3 ml (milliliters) of physiological saline (0.9% NaCl).
[0163] This dosage of the active ingredient of the new medicament was selected based on previous studies that demonstrated therapeutic efficacy with an adequate safety profile in this dosage range.
[0164] The subcutaneous route was chosen for providing adequate systemic absorption with ease of administration and good tolerability by the animals.
[0165] The applications were performed in a standardized manner, always on the same day of the week and in the same period of the day, to minimize circadian variations that could influence the therapeutic response.
[0166] The application site was alternated between different subcutaneous regions to avoid local irritation and ensure uniform absorption of the medicament. The results are presented below, but at no time do they intend to reduce or limit the reach and scope of the present disclosure.EVALUATION INSTRUMENT
[0167] The Canine Brief Pain Inventory (CBPI) questionnaire - Brief inventory of canine pain (Brown DC et al, 2008;) was used for the evaluation of the pain intensity associated with the state of articular inflammation.
[0168] The evaluation of pain in animals constitutes a significant methodological challenge, since veterinary patients, unlike human beings, cannot verbally communicate their painful experience.
[0169] In this context, the Canine Brief Pain Inventory (CBPI) represents a validated and widely recognized instrument for the measurement of pain and its functional impact in dogs and other animals
[0170] This questionnaire, adapted from the human Brief Pain Inventory (BPI), allows a multidimensional evaluation of the painful experience, contemplating both the intensity of the pain and its impact on the functional activities of the animal.
[0171] The CBPI evaluates four main dimensions of the painful experience in animals:— the level of most intense pain experienced in the last seven days, — the level of least intense pain in the same period,— the level of average pain— the level of pain present at the moment of the evaluation.
[0172] Additionally, the instrument measures the impact of pain on specific activities such as locomotion capacity oy of living, general activities, and capacity to perform specific movements such as standing up, walking, running, and climbing stairs.EVALUATION CRITERIA
[0173] The reduction of >1 point in the PSS associated with the reduction of >2 points in the PIS in relation to the baseline value was adopted as the operational definition of therapeutic success evaluated by the questionnaire (CBPI), which represents a criterion identical to that adopted in the pivotal studies of Bedinvetmab, which is a biological therapy recently licensed by the FDA for canine arthritis arthrosis based on evaluations using the CBPI (FDA / NADA 2023).VETERINARY PROTOCOL — SUMMARIZED ANALYSIS
[0174] For the purposes of summarizing the analysis of the 42 (forty-two) dogs involved in the veterinary protocol, the results of all animals were specially selected for more in-depth discussion in this specification.
[0175] However, without these presented results intending at any time to diminish or limit the utility of the present disclosure.
[0176] The summarized results of 42 (forty-two) animals are presented below.
[0177] Results of Pain Evaluation by the CBPI:
[0178] The results of these 42 (forty-two) animals - calculated jointly - demonstrated statistically significant improvement in all domains evaluated by the CBPI CBPI-. CONVENTIONS USED AND PARAMETERS OF THE 42 ANIMALS INVOLVED IN THE STUDYTable 1. Classification of the responses to the treatmentResponse category N % Meaning CBPI THERAPEUTIC i 14 33.3% Meets the officialSUCCESS i criterion PSS > 1 and (PIS > 2 PARTIAL i 9 21.4% Response present, but IMPROVEMENT below the official i threshold FLOOR EFFECT i 7 16.7% Borderline baseline i (oligosymptoinatic).i with reduced margin for i demonstrating effect NON-RESPONSE 9 21.4% Variation < 10% or i worsening TREATMENT- i 3 7.1% Low adherence with DEPENDENT i documented adhcrcncc- EFFICACY i improv cinenl correlation EXPERIMENTAL GROUP — RESPONSE: VARIATION OF EFFECTS IN 42 ANIMALS
[0179] Clinical trial: Variation of the effect in the animals: some animals presented a reduced response to the application of the present disclosure (16.7%), and a small group did not present an effect (7.1%)
[0180] Some of the possible reasons may be related to the short duration of the clinical trial (4 to 7 weekly applications).
[0181] Another point to be considered is that the response to medicaments in veterinary patients — just as occurs in humans — can be the result of individual differences in terms of genetics, age, weight / body composition, metabolic rate (hepatic / renal function) drug interactions (Merck Veterinary Manual 2024)
[0182] Furthermore, these results suggest that a longer duration of the treatment with the present disclosure should be considered for animals that respond poorly or do not respond at all.
[0183] However, these events do not alter the practical utility of the present disclosure for use in the treatment of arthritis and osteoarthritis, given its therapeutic success rate of 33.3%, determined by the operational criterion adopted in this study (reduction > 1 point in the PSS associated with reduction > 2 points in the PIS), and its global response rate of 54.7%, which corresponds to the therapeutic success rate (33.3%) added to the partial improvement (21.4%) — these rates being superior to those of the majority of the currently available medicaments in the prior art used to treat the same conditions and clinical pathologies.
[0184] Abbreviations used in the clinical trial:— PSS: Pain Severity Score— PIS: Pain Interference ScoreCase CPI
[0185] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 51 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 2. Case CPIPSS(O-IO) PIS - ( _0_-10) Overa !ll2CBPIBaseline i 0.8 Best response (visit 4 of 0.0 0.0 0.0 (| 100%)6 / Final I i 0.0 0.0 0.0 Variation (baseline i J. 0.8 J 1.7 j. 1.2 (100%) final) iCONCLUSION / COMMENT S
[0186] Case classified as FLOOR EFFECT (floor effect). The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 1.2), with scores already close to the floor of the scale. In this condition, the arithmetic margin available for the demonstration of reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0187] The PSS reduced from 0.8 to 0.0 (reduction of 0.8 points); the PIS reduced from 1.7 to 0.0 (reduction of 1.7 points); the Overall CBPI reduced from 1.2 to 0.0, corresponding to a reduction of 100%.
[0188] In effect, there was practically complete normalization of the scores (100% of reduction), without the formal criterion of success being able to be arithmetically achieved.
[0189] Analysis of the best response under treatment: in the 4th of 6 evaluations, the subject achieved PSS of 0.0, PIS of 0.0, and Overall CBPI of 0.0 — reduction of 100% in relation to the baseline value.
[0190] The obtained effect was maintained until the end of the follow-up, without relevant relapse.Case CP2
[0191] Clinical synthesis: Canine subject, female, Pinscher breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 joint radiographic examination; 1 joint ultrasonographic examination. Table 3. Case CP2PSS (0-10) PIS (0-10) Overall CBPI Baseline i 0.2 1.8 1.0 Best response (visit 3 of I 0.0 0.0 0.0 (J. 100%) 72) ' L Final i 0.0 0.0 0.0 Variation (baseline i J. 0.2 J. 1.8 J. 1.0 (100%) final) iCONCLUSION / COMMENT S
[0192] Case classified as FLOOR EFFECT (floor effect). The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 1.0), with scores already close to the floor of the scale. In this condition, the arithmetic margin available for the demonstration of reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0193] The PSS reduced from 0.2 to 0.0 (reduction of 0.2 points); the PIS reduced from 1.8 to 0.0 (reduction of 1.8 points); the Overall CBPI reduced from 1.0 to 0.0, corresponding to a reduction of 100%.
[0194] In effect, there was practically complete normalization of the scores (100% of reduction), without the formal criterion of success being able to be arithmetically achieved.
[0195] Analysis of the best response under treatment: in the 3rd of 12 evaluations, the subject achieved PSS of 0.0, PIS of 0.0, and Overall CBPI of 0.0 — reduction of 100% in relation to the baseline value.
[0196] The obtained effect was maintained until the end of the follow-up, without relevant relapse.Case CP3
[0197] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 90 days, with 15 serial evaluations by the Canine Brief Pain Inventory (CBPI). Referred to complaint of chronic articular pain. The initial radiography documented narrowing of the articular space and periarticular osteophytosis compatible with established osteoarthritis, and the two serial ultrasonographic examinations documented baseline joint effusion with progressive normalization throughout the treatment. Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 joint radiographic examination; 2 joint ultrasonographic examinations.Table 4. Case CP3PSS (0-10) PIS (0-10) Overall CBPI Baseline i 3.8 6.7 5.2 Best response (visit 14 s 0.0 0.3 0.2 (J. 97%) of!5) Final 0.0 0.3 0.2Variation (baseline — > J. 3.8 J. 6.4 J. 5.0 (97%) final) iCONCLUSION / COMMENT S
[0198] Case classified as CBPI THERAPEUTIC SUCCESS. Fully meets the operational criterion of success adopted in this study — reduction of at least 1 pointin the PSS associated with the reduction of at least 2 points in the PIS: the reduction of the PSS was of 3.8 points and that of the PIS, of 6.4 points.
[0199] The PSS reduced from 3.8 to 0.0 (reduction of 3.8 points); the PIS reduced from 6.7 to 0.3 (reduction of 6.4 points); the Overall CBPI reduced from 5.2 to 0.2, corresponding to a reduction of 97%.
[0200] Analysis of the best response under treatment: in the 14th of 15 evaluations, the subject reached a PSS of 0.0, PIS of 0.3 and Overall CBPI of 0.2 — a reduction of 97% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.8 points in the PSS and of 6.4 points in the PIS).
[0201] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP4
[0202] Clinical synthesis: Canine subject, female, mixed breed. Follow-up of 50 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 5. Case CP4PSS (0-10) PIS (0-10) Overall CBPI Baseline i 3.0 1.5 2.2 Best response i 0.0 0.0 0.0 (J. 100%)Final i 0.2 0.0 0.1 Variation (baseline — > J. 2.8 J. 1.5 J. 2.1 (94%) final) iCONCLUSION / COMMENT S
[0203] Case classified as FLOOR EFFECT. The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 2.2), with scores already close to the floor of the scale. In this condition, the arithmetic margin availablefor the demonstration of reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0204] The PSS reduced from 3.0 to 0.2 (reduction of 2.8 points); the PIS reduced from 1.5 to 0.0 (reduction of 1.5 points); the Overall CBPI reduced from 2.2 to 0.1, corresponding to a reduction of 94%.
[0205] In effect, there was practically complete normalization of the scores (94% of reduction), without the formal criterion of success being able to be arithmetically reached.
[0206] Analysis of the best response under treatment: in the 4th of 6 evaluations, the subject reached a PSS of 0.0, PIS of 0.0 and Overall CBPI of 0.0 — a reduction of 100% in relation to the baseline value.
[0207] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP5
[0208] Clinical synthesis: Canine subject, female, mixed breed. Follow-up of 90 days, with 11 serial evaluations by the Canine Brief Pain Inventory (CBPI). Referred to a condition of advanced osteoarthritis, with baseline presentation Overall CBPI of 8.7 (extreme severity). The initial radiographic and ultrasonographic evaluations documented severe joint compromise. Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular radiographic examination; 1 joint ultrasonographic examination.Table 6. Case CP5PSS (0-10) PIS (0-10) Overall CBPI Baseline i 8.0 9.3 8.7 Best response (visit 10 i 0.0 1.7 0.8 (J. 90%) ofH) | Final i 0.0 1.7 0.8 Variation (baseline ; J. 8.0 J. 7.6 J. 7.9 (90%)final) iCONCLUSION / COMMENT S
[0209] Case classified as CBPI THERAPEUTIC SUCCESS. Fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with the reduction of at least 2 points in the PIS: the reduction of the PSS was of 8.0 points and that of the PIS, of 7.6 points.
[0210] The PSS reduced from 8.0 to 0.0 (reduction of 8.0 points); the PIS reduced from 9.3 to 1.7 (reduction of 7.6 points); the Overall CBPI reduced from 8.7 to 0.8, corresponding to a reduction of 90%.
[0211] Analysis of the best response under treatment: in the 10th of 11 evaluations, the subject reached a PSS of 0.0, PIS of 1.7 and Overall CBPI of 0.8 — a reduction of 90% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 8.0 points in the PSS and of 7.6 points in the PIS).
[0212] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP6
[0213] Clinical synthesis: Canine subject, male, mixed breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Referred with a main complaint of accentuated functional compromise (baseline PIS of 9.0, close to the ceiling of the scale). The radiographic evaluation documented established osteoarthritis. Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 joint radiographic examination.Table 7. Case CP6PSS (0-10) PIS (0-10) Overall CBPI Baseline i 4.2 9.0 6.6 Best response (visit 10 i 1.2 1.0 1.1 (j. 83%) of!2) | Final i 1.2 1.0 1.1 Variation (baseline ; J. 3.0 J. 8.0 J. 5.5 (83%)final) iCONCLUSION / COMMENT S
[0214] Case classified as CBPI THERAPEUTIC SUCCESS. Fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with the reduction of at least 2 points in the PIS: the reduction of the PSS was of 3.0 points and that of the PIS, of 8.0 points.
[0215] The PSS reduced from 4.2 to 1.2 (reduction of 3.0 points); the PIS reduced from 9.0 to 1.0 (reduction of 8.0 points); the Overall CBPI reduced from 6.6 to 1.1, corresponding to a reduction of 83%.
[0216] The percentage reduction of the interference block exceeded that of the intensity block, suggesting that the compound restores articular function beyond direct nociceptive symptomatic relief — a finding consistent with the hypothesis of an immunomodulatory mechanism acting on the joint inflammatory microenvironment.
[0217] Analysis of the best response under treatment: in the 10th of 12 evaluations, the subject reached a PSS of 1.2, PIS of 1.0 and Overall CBPI of 1.1 — a reduction of 83% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.0 points in the PSS and of 8.0 points in the PIS).
[0218] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP7
[0219] Clinical synthesis: Canine subject, male, Golden Retriever breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 2 articular radiographic examinations; 1 joint ultrasonographic examination.Table 8. Case CP7PSS (0-10) PIS (0-10) Overall CBPI Baseline i 3.8 0.8 2.3 Best response (visit 11 i 0.8 0.2 0.5 (J. 80%) of!2)Final i 0.8 0.2 0.5 Variation (baseline — > J. 3.0 J. 0.6 J. 1.8 (80%) final) iCONCLUSION / COMMENT S
[0220] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (0.6 points) fell short of the minimum of 2 points.
[0221] The PSS reduced from 3.8 to 0.8 (reduction of 3.0 points); the PIS reduced from 0.8 to 0.2 (reduction of 0.6 points); the Overall CBPI reduced from 2.3 to 0.5, corresponding to a reduction of 80%.
[0222] Note that the baseline interference score was already close to the floor of the scale (0.8), which structurally limits the arithmetic margin available for the reduction of 2 points required by the criterion.
[0223] Analysis of the best response under treatment: in the 11th of 12 evaluations, the subject reached a PSS of 0.8, PIS of 0.2 and Overall CBPI of 0.5 — a reduction of 80% in relation to the baseline value.
[0224] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP8
[0225] Clinical synthesis: Canine subject, female, Basset Hound breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Basset Hound breed, chondrodysplastic, with recognized predisposition to early degenerative joint disease. Veterinary literature recognizes chondrodysplastic breeds as clinically representative models of human joint pathology with an early degenerative component. Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of thepresent disclosure; 1 joint radiographic examination; 1 joint ultrasonographic examination.Table 9. Case CP8PSS (0-10) PIS (0-10) Overall CBPI Baseline i 7.2 8.7 8.0 Best response (visit 12 s 2.0 1.8 1.9 (J. 76%) of!2)Final 2.0 1.8 1.9 Variation (baseline i J. 5.2 J. 6.9 J. 6.1 (76%) final) iCONCLUSION / COMMENT S
[0226] Case classified as CBPI THERAPEUTIC SUCCESS. Fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with the reduction of at least 2 points in the PIS: the reduction of the PSS was of 5.2 points and that of the PIS, of 6.9 points.
[0227] The PSS reduced from 7.2 to 2.0 (reduction of 5.2 points); the PIS reduced from 8.7 to 1.8 (reduction of 6.9 points); the Overall CBPI reduced from 8.0 to 1.9, corresponding to a reduction of 76%.
[0228] Analysis of the best response under treatment: in the 12th of 12 evaluations, the subject reached a PSS of 2.0, PIS of 1.8 and Overall CBPI of 1.9 — a reduction of 76% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 5.2 points in the PSS and of 6.9 points in the PIS).
[0229] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP9
[0230] Clinical synthesis: Canine subject, male, Chihuahua breed. Follow-up of 50 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 7 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject;the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 10. Case CP9PSS (0-10) PIS (0-10) Overall CBPI Baseline i 7.0 5.7 6.3 Best response (visit 6 of s 2.0 2.0 2.0 (J. 68%) cFinal i 2.0 2.0 2.0 Variation (baseline — > J. 5.0 J. 3.7 J. 4.3 (68%) final) iCONCLUSION / COMMENT S
[0231] Case classified as CBPI THERAPEUTIC SUCCESS. Fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with the reduction of at least 2 points in the PIS: the reduction of the PSS was of 5.0 points and that of the PIS, of 3.7 points.
[0232] The PSS reduced from 7.0 to 2.0 (reduction of 5.0 points); the PIS reduced from 5.7 to 2.0 (reduction of 3.7 points); the Overall CBPI reduced from 6.3 to 2.0, corresponding to a reduction of 68%.
[0233] Analysis of the best response under treatment: in the 6th of 6 evaluations, the subject reached a PSS of 2.0, PIS of 2.0 and Overall CBPI of 2.0 — a reduction of 68% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 5.0 points in the PSS and of 3.7 points in the PIS).
[0234] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP10
[0235] Clinical synthesis: Canine subject, female, mixed breed. Follow-up of 35 days, with 5 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. Thereis no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 11. Case CP 10PSS (0-10) PIS (0-10) Overall CBPI Baseline i 4.8 7.3 6.0 Best response (visit 5 of s 1.8 2.2 2.0 (J. 68%) 5)Final 1.8 2.2 2.0 Variation (baseline i J. 3.0 J. 5.1 J. 4.0 (68%) final) iCONCLUSION / COMMENT S
[0236] Case classified as CBPI THERAPEUTIC SUCCESS. Fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with the reduction of at least 2 points in the PIS: the reduction of the PSS was of 3.0 points and that of the PIS, of 5.1 points.
[0237] The PSS reduced from 4.8 to 1.8 (reduction of 3.0 points); the PIS reduced from 7.3 to 2.2 (reduction of 5.1 points); the Overall CBPI reduced from 6.0 to 2.0, corresponding to a reduction of 68%.
[0238] Analysis of the best response under treatment: in the 5th of 5 evaluations, the subject reached a PSS of 1.8, PIS of 2.2 and Overall CBPI of 2.0 — a reduction of 68% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.0 points in the PSS and of 5.1 points in the PIS).
[0239] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CPU
[0241] Clinical synthesis: Canine subject, female, Boxer breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 joint radiographic examination; 1 joint ultrasonographic examination.Table 12. Case CPUPSS (0-10) PIS (0-10) Overall CBPI Baseline i 3.8 2.8 Best response i 1.0 1.2 1.1 Q 67%)Final i 1.0 1.2 1.1 Variation (baseline i J. 2.8 1 1.6 ) 2.2 (67%) final) iCONCLUSION / COMMENT S
[0242] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (1.6 points) fell short of the minimum of 2 points.
[0243] The PSS reduced from 3.8 to 1.0 (reduction of 2.8 points); the PIS reduced from 2.8 to 1.2 (reduction of 1.6 points); the Overall CBPI reduced from 3.3 to 1.1, corresponding to a reduction of 67%.
[0244] Analysis of the best response under treatment: in the 7th of 12 evaluations, the subject reached a PSS of 1.0, PIS of 1.2 and Overall CBPI of 1.1 — a reduction of 67% in relation to the baseline value.
[0245] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP12
[0246] Clinical synthesis: Canine subject, sex not informed, without defined breed. Follow-up of 50 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal. There is no complete blood count registered in the database for this subject. Table 13. Case CP 12PSS (0-10) PIS (0-10) Overa --ll---CBPI Baseline i 6.0 5.8. Best response (visit 5 of I 3.0 1.0 2.0 (I 66%) C ' I Final i 3.0 1.0 2.0 Variation (baseline i 1 3.0 1 4.8 1 3.9 (66%)final) iCONCLUSION / COMMENT S
[0247] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was 3.0 points and that of the PIS, 4.8 points.
[0248] The PSS reduced from 6.0 to 3.0 (reduction of 3.0 points); the PIS reduced from 5.8 to 1.0 (reduction of 4.8 points); the Overall CBPI reduced from 5.9 to 2.0, corresponding to a reduction of 66%.
[0249] Analysis of the best response under treatment: in the 5th of 6 evaluations, the subject reached a PSS of 3.0, PIS of 1.0 and Overall CBPI of 2.0 — a reduction of 66% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.0 points in the PSS and of 4.8 points in the PIS).
[0250] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP13
[0251] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 35 days, with 5 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 14. Case CP 13PSS (0-10) PIS (0-10) Overall ( DPI Baseline i 5.2 4.2 4.7 Best response (visit 5 of i 2.0 1.7 1.8 (J. 61%) 5)Final i 2.0 1.7 1.8 Variation (baseline — > i J. 3.2 J. 2.5 J. 2.9 (61%) final) iCONCLUSION / COMMENT S
[0252] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was 3.2 points and that of the PIS, 2.5 points.
[0253] The PSS reduced from 5.2 to 2.0 (reduction of 3.2 points); the PIS reduced from 4.2 to 1.7 (reduction of 2.5 points); the Overall CBPI reduced from 4.7 to 1.8, corresponding to a reduction of 61%.
[0254] Analysis of the best response under treatment: in the 5th of 5 evaluations, the subject reached a PSS of 2.0, PIS of 1.7 and Overall CBPI of 1.8 — a reduction of 61% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.2 points in the PSS and of 2.5 points in the PIS).
[0255] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP14
[0256] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular radiographic examination; 1 joint ultrasonographic examination.Table 15. Case CP 14PSS (0-10) PIS (0-10) Overall CBPI Baseline i 7.0 7.7 7.3 Best response (visit 12 s 3.0 3.0 3.0 (J. 59%) of!2)Final i 3.0 3.0 3.0 Variation (baseline — > J. 4.0 J. 4.7 J. 4.3 (59%) final) iCONCLUSION / COMMENT S
[0257] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was 4.0 points and that of the PIS, 4.7 points.
[0258] The PSS reduced from 7.0 to 3.0 (reduction of 4.0 points); the PIS reduced from 7.7 to 3.0 (reduction of 4.7 points); the Overall CBPI reduced from 7.3 to 3.0, corresponding to a reduction of 59%.
[0259] Analysis of the best response under treatment: in the 12th of 12 evaluations, the subject reached a PSS of 3.0, PIS of 3.0 and Overall CBPI of 3.0 — a reduction of 59% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 4.0 points in the PSS and of 4.7 points in the PIS).
[0260] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP15
[0261] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 56 days, with 8 serial evaluations by the Canine Brief Pain Inventory (CBPI). Subject with an integral set of evidence — clinical, radiological, ultrasonographic and laboratory — , which makes the case especially suitable for substantiating the practical use of the present disclosure, simultaneously meeting the requirements of clinical evidence and exclusion of toxicity. Complementary documentation available: 3 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular radiographic examination; 1 joint ultrasonographic examination.Table 16. Case CP 15PSS(O-IO) PIS (0-10) Overa --l-l-- CBPI Baseline i 5.0 7.8 Best response (visit 7 of \ 3.0 2.5 2.8 (I 57%) 8) ' | Final i 3.0 2.5 2.8 Variation (baseline i J. 2.0 1 5.3 1 3.6 (57%) final) iCONCLUSION / COMMENT S
[0262] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was 2.0 points and that of the PIS, 5.3 points.
[0263] The PSS reduced from 5.0 to 3.0 (reduction of 2.0 points); the PIS reduced from 7.8 to 2.5 (reduction of 5.3 points); the Overall CBPI reduced from 6.4 to 2.8, corresponding to a reduction of 57%.
[0264] Analysis of the best response under treatment: in the 7th of 8 evaluations, the subject reached a PSS of 3.0, PIS of 2.5 and Overall CBPI of 2.8 — a reduction of 57% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 2.0 points in the PSS and of 5.3 points in the PIS).
[0265] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP16
[0266] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 2 articular radiographic examinations; 1 joint ultrasonographic examination.Table 17. Case CP 16PSS (0-10) PIS (0-10) Overa --l-l--- CBPI Baseline i 2.8 1.5. Best response (visit 10 I 1.0 1.0 1.0 a 53%) of!2) | Final i 1.0 1.0 1.0 Variation (baseline — > i J. 1.8 10.5 1 1.1 (53%) final) iCONCLUSION / COMMENT S
[0267] Case classified as FLOOR EFFECT. The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 2.1), with scores already close to the floor of the scale. In this condition, the arithmetic margin available for demonstrating reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0268] The PSS reduced from 2.8 to 1.0 (reduction of 1.8 points); the PIS reduced from 1.5 to 1.0 (reduction of 0.5 points); the Overall CBPI reduced from 2.1 to 1.0, corresponding to a reduction of 53%.
[0269] Analysis of the best response under treatment: in the 10th of 12 evaluations, the subject reached a PSS of 1.0, PIS of 1.0 and Overall CBPI of 1.0 — a reduction of 53% in relation to the baseline value.
[0270] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP17
[0271] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 92 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 2 articular radiographic examinations.Table 18. Case CP 17PSS (0-10) PIS (0-10) Overall (’DPI Baseline i 4.8 5.3 5.0 Best response (visit 12 i 2.0 3.3 2.7 (J. 47%) ofl2)Final 2.0 3.3 2.7 Variation (baseline — > i J. 2.8 J. 2.0 J. 2.3 (47%) final) iCONCLUSION / COMMENT S
[0272] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was 2.8 points and that of the PIS, 2.0 points.
[0273] The PSS reduced from 4.8 to 2.0 (reduction of 2.8 points); the PIS reduced from 5.3 to 3.3 (reduction of 2.0 points); the Overall CBPI reduced from 5.0 to 2.7, corresponding to a reduction of 47%.
[0274] Analysis of the best response under treatment: in the 12th of 12 evaluations, the subject reached a PSS of 2.0, PIS of 3.3 and Overall CBPI of 2.7 — a reduction of 47% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 2.8 points in the PSS and of 2.0 points in the PIS).
[0275] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP18
[0276] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 421 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Subject with the longest follow-up of the cohort: 421 days (approximately 14 months) of continuous follow-up under the experimental protocol. Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular ultrasonographic examination. There is no radiographic report registered inthe database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 19. Case CP 18PSS (0-10) PIS (0-10) Overall CBPI Baseline i 5.2 6.2 5.7 Best response (visit 10 s 4.0 3.2 3.6 (J. 37%) of!2)Final i 4.0 3.2 3.6 Variation (baseline — > i J. 1.2 J. 3.0 J. 2.1 (37%) final) iCONCLUSION / COMMENT S
[0277] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was 1.2 points and that of the PIS, 3.0 points.
[0278] The PSS reduced from 5.2 to 4.0 (reduction of 1.2 points); the PIS reduced from 6.2 to 3.2 (reduction of 3.0 points); the Overall CBPI reduced from 5.7 to 3.6, corresponding to a reduction of 37%.
[0279] It should be noted that this subject did not present a perceptible loss of efficacy in continued use for more than one year (421 days), which is essential for the use of the present disclosure in a chronic disease such as osteoarthritis. Additionally, the result attests to the absence of relevant and cumulative toxicity in prolonged use.
[0280] Analysis of the best response under treatment: in the 10th of 12 evaluations, the subject reached a PSS of 4.0, PIS of 3.2 and Overall CBPI of 3.6 — a reduction of 37% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 1.2 points in the PSS and of 3.0 points in the PIS).
[0281] The effect obtained was maintained until the end of the follow-up, without relevant relapses.Case CP19
[0282] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 21 days, with 4 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 20. Case CP 19PSS (0-10) PIS (0-10) Overall CBPI Baseline i 7.0 8.2 7.6 Best response (visit 3 of s 2.8 3.0 2.9 (J. 62%)4) ' | _____ _ Final : 3.5 6.7 5.1 Variation (baseline — > J. 3.5 J. 1.5 J. 2.5 (33%) final) iCONCLUSION / COMMENT S
[0283] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (1.5 points) fell short of the minimum of 2 points.
[0284] The PSS reduced from 7.0 to 3.5 (reduction of 3.5 points); the PIS reduced from 8.2 to 6.7 (reduction of 1.5 points); the Overall CBPI reduced from 7.6 to 5.1, corresponding to a reduction of 33%.
[0285] The follow-up of this subject was short (21 days, 4 evaluations), which may have limited the full expression of the therapeutic effect.
[0286] Analysis of the best response under treatment: in the 3rd of 4 evaluations, the subject reached a PSS of 2.8, PIS of 3.0 and Overall CBPI of 2.9 — a reduction of 62% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 4.2 points in the PSS and of 5.2 points in the PIS).
[0287] The final score, of 5.1, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 2.2 points in the Overall CBPI).
[0288] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result not having been maintained until the end of the follow-up. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP20
[0289] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 91 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Subject of the same owner as CPI 8, which allows informal control of environmental and management factors between the two animals. Complementary documentation available: 4 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 joint radiographic examination; 1 joint ultrasonographic examination.Table 21. Case CP20PSS (0-10) PIS (0-10) Overall CBPI Baseline i 6.2 7.3 6.8 Best response (visit 10 i 4.0 3.2 3.6 (J. 47%) of!2)Final i 5.0 4.2 4.6 Variation (baseline — > i J. 1.2 J. 3.1 J. 2.2 (33%) final) iCONCLUSION / COMMENT S
[0290] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was of 1.2 points and that of the PIS, of 3.1 points.
[0291] The PSS reduced from 6.2 to 5.0 (reduction of 1.2 points); the PIS reduced from 7.3 to 4.2 (reduction of 3.1 points); the Overall CBPI reduced from 6.8 to 4.6, corresponding to a reduction of 33%.
[0292] Analysis of the best response under treatment: in the 10th of 12 evaluations, the subject reached a PSS of 4.0, PIS of 3.2 and Overall CBPI of 3.6 — a reduction of 47% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 2.2 points in the PSS and of 4.1 points in the PIS).
[0293] The final score, of 4.6, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 1.0 points in the Overall CBPI).Case CP21
[0294] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 69 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular radiographic examination.Table 22. Case CP21PSS (0-10) PIS (0-10) Overall ( DPI Baseline i 5.0 4.8 4.9 Best response (visit 3 of I 2.0 2.8 2.4 (J. 51%)7 / ' Final 3.2 3.7 3.5 Variation (baseline — > J. 1.8 J. 1.1 J. 1.4 (30%) final) iCONCLUSION / COMMENT S
[0295] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (1.1 points) fell short of the minimum of 2 points.
[0296] The PSS reduced from 5.0 to 3.2 (reduction of 1.8 points); the PIS reduced from 4.8 to 3.7 (reduction of 1.1 points); the Overall CBPI reduced from 4.9 to 3.5, corresponding to a reduction of 30%.
[0297] Analysis of the best response under treatment: in the 3rd of 7 evaluations, the subject reached a PSS of 2.0, PIS of 2.8 and Overall CBPI of 2.4 — a reduction of51% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.0 points in the PSS and of 2.0 points in the PIS).
[0298] The final score, of 3.5, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapses of 1.0 points in the Overall CBPI). It should be registered that the deterioration succeeded an interruption of 19 days between applications, greater than the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.
[0299] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result having been lost only following the interruption of the applications. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP22
[0300] Clinical synthesis: Canine subject, male, Border Collie breed. Follow-up of 78 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 23. Case CP22PSS (O-IO) PIS (0 -10) Overall CBPI Baseline i 5.0 7.7 Best response (visit 4 of i 3.8 4.0 3.9 (I 39%)7 / 'Final i 3.8 5.2 4.5 Variation (baseline — > i | 1.2 J. 2.5 1 1.8 (30%) final) iCONCLUSION / COMMENT S
[0301] Case classified as CBPI THERAPEUTIC SUCCESS. It fully meets the operational criterion of success adopted in this study — reduction of at least 1 point in the PSS associated with a reduction of at least 2 points in the PIS: the reduction of the PSS was of 1.2 points and that of the PIS, of 2.5 points.
[0302] The PSS reduced from 5.0 to 3.8 (reduction of 1.2 points); the PIS reduced from 7.7 to 5.2 (reduction of 2.5 points); the Overall CBPI reduced from 6.3 to 4.5, corresponding to a reduction of 30%.
[0303] Analysis of the best response under treatment: in the 4th of 7 evaluations, the subject reached a PSS of 3.8, PIS of 4.0 and Overall CBPI of 3.9 — a reduction of 39% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 1.2 points in the PSS and of 3.7 points in the PIS).
[0304] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP23
[0306] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 74 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Subject with extreme baseline severity (Overall CBPI 9.3). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 24. Case CP23PSS (0-10) PIS (0-10) Overall CBPIBaseline i 9.0 9.7 9.3 Best response (visit 5 of i 3.8 7.8 5.8 (J. 38%)7 / ' LFinal 5.2 8.0 6.6 Variation (baseline ; J. 3.8 J. 1.7 J. 2.7 (29%) final) iCONCLUSION / COMMENT S
[0307] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (1.7 points) fell short of the minimum of 2 points.
[0308] The PSS reduced from 9.0 to 5.2 (reduction of 3.8 points); the PIS reduced from 9.7 to 8.0 (reduction of 1.7 points); the Overall CBPI reduced from 9.3 to 6.6, corresponding to a reduction of 29%.
[0309] Analysis of the best response under treatment: in the 5th of 7 evaluations, the subject reached a PSS of 3.8, PIS of 7.8 and Overall CBPI of 5.8 — a reduction of 38% in relation to the baseline value.
[0310] The effect obtained was maintained until the end of the follow-up, without relevant relapse.Case CP24
[0311] Clinical synthesis: Canine subject, female, Golden Retriever breed. Follow-up of 83 days, with 11 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 2 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular radiographic examination; 1 joint ultrasonographic examination.Table 25. Case CP24PSS (0-10) PIS (0-10) Overall CBPIBaseline i 5.0 5.0 5.0 Best response (visit 7 of s 2.8 2.0 2.4 (J. 52%)U) ?Final 5.0 2.2 3.6 Variation (baseline i = 0.0 J. 2.8 J. 1.4 (28%) final) iCONCLUSION / COMMENT S
[0312] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PSS (0.0 points) fell short of the minimum of 1 point.
[0313] The PSS remained unchanged at 5.0 (without variation); the PIS reduced from 5.0 to 2.2 (reduction of 2.8 points); the Overall CBPI reduced from 5.0 to 3.6, corresponding to a reduction of 28%.
[0314] Analysis of the best response under treatment: in the 7th of 11 evaluations, the subject reached a PSS of 2.8, PIS of 2.0 and Overall CBPI of 2.4 — a reduction of 52% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 2.2 points in the PSS and of 3.0 points in the PIS).
[0315] The final score, of 3.6, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapses of 1.2 points in the Overall CBPI).
[0316] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result not having been maintained until the end of the follow-up. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP25
[0317] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 99 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 7 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 26. Case CP25PSS (0-10) PIS (0-10) Overall CBPI Baseline i 1.2 2.8 2.0Best response (visit 5 of 1 0.0 0.7 0.3 (J. 84%)7) [Final i 1.0 2.0 1.5 Variation (baseline — A | 0.2 J. 0.8 J. 0.5 (27%)final)CONCLUSION / COMMENT S
[0318] Case classified as FLOOR EFFECT (floor effect). The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 2.0), with scores already close to the floor of the scale. In this condition, the arithmetic margin available for demonstration of reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0319] The PSS reduced from 1.2 to 1.0 (reduction of 0.2 points); the PIS reduced from 2.8 to 2.0 (reduction of 0.8 points); the Overall CBPI reduced from 2.0 to 1.5, corresponding to a reduction of 27%.
[0320] Analysis of the best response under treatment: in the 5th of 7 evaluations, the subject reached a PSS of 0.0, PIS of 0.7 and Overall CBPI of 0.3 — a reduction of 84% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 1.2 points in the PSS and of 2.1 points in the PIS).
[0321] The final score, of 1.5, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 1.2 points in the Overall CBPI). It should be registered that the deterioration succeeded an interruption of 50 days between applications, greater than the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.
[0322] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result having been lost only following the interruption of the applications. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP26
[0323] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 77 days, with 8 serial evaluations by the Canine Brief Pain Inventory (CBPI).Subject with baseline interference score at the ceiling of the scale (PIS 10.0). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 27. Case CP26PSS (0-10) PIS (0-10) Overall CBPI Baseline i 7.510.08.8Best response i 5.0 9.3 7.2 (J. 18%) Final i 5.0 9.3 7.2Variation (baseline — >• N 2.5 J. 0.7 J. 1.6 (18%)final)CONCLUSION / COMMENT S
[0324] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (0.7 points) fell short of the minimum of 2 points.
[0325] The PSS reduced from 7.5 to 5.0 (reduction of 2.5 points); the PIS reduced from 10.0 to 9.3 (reduction of 0.7 points); the Overall CBPI reduced from 8.8 to 7.2, corresponding to a reduction of 18%.
[0326] Analysis of the best response under treatment: in the 8th of 8 evaluations, the subject reached a PSS of 5.0, PIS of 9.3 and Overall CBPI of 7.2 — a reduction of 18% in relation to the baseline value.Case CP27
[0327] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 14 days, with 3 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 2 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 2 articular radiographic examinations; 1 joint ultrasonographic examination.Table 28. Case CP27PSS (ii-ni) Pis (ii-io) Overall CBPI Baseline i 7.06.76.8Best response (visit 2 of 6.0 5.7 5.8 (1 15%)3) |Final i 6.0 5.7 5.8Variation (baseline —> J. 1.0 J. 1.0 1 1.0 (15%)final) iCONCLUSION / COMMENT S
[0328] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PIS (1.0 points) fell short of the minimum of 2 points.
[0329] The PSS reduced from 7.0 to 6.0 (reduction of 1.0 points); the PIS reduced from 6.7 to 5.7 (reduction of 1.0 points); the Overall CBPI reduced from 6.8 to 5.8, corresponding to a reduction of 15%.
[0330] The follow-up of this subject was short (14 days, 3 evaluations), which may have limited the full expression of the therapeutic effect.
[0331] Analysis of the best response under treatment: in the 2nd of 3 evaluations, the subject reached PSS of 6.0, PIS of 5.7 and Overall CBPI of 5.8 — reduction of 15% in relation to the baseline value.Case CP28
[0332] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 56 days, with 8 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 3 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 articular radiographic examination; 1 joint ultrasonographic examination.Table 29. Case CP28PSS (0-10) PIS (0-10) 6.’ ... O....v...e..r..a...l.l... C...B....P...I.... Baseline i 6.0 7.3 Best response (visit 5 of I 3.2 3.2 3.2 (| 52%)8) Final 5.2 6.5 5.9 Variation (baseline — | 0.8 J. 0.8 ) 0.8 (12%) final) iCONCLUSION / COMMENT S
[0333] Case classified as PARTIAL IMPROVEMENT. There is documented therapeutic response, however below the operational threshold of success, since the reduction of the PSS (0.8 points) fell short of the minimum of 1 point and the reduction of the PIS (0.8 points) fell short of the minimum of 2 points.
[0334] The PSS reduced from 6.0 to 5.2 (reduction of 0.8 points); the PIS reduced from 7.3 to 6.5 (reduction of 0.8 points); the Overall CBPI reduced from 6.7 to 5.9, corresponding to a reduction of 12%.
[0335] Analysis of the best response under treatment: in the 5th of 8 evaluations, the subject reached PSS of 3.2, PIS of 3.2 and Overall CBPI of 3.2 — reduction of 52% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 2.8 points in the PSS and of 4.1 points in the PIS).
[0336] The final score, of 5.9, is higher than the best value obtained, which translates to a loss of the therapeutic effect along the follow-up (relapse of 2.7 points in the Overall CBPI).
[0337] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result not having been maintained until the end of the follow-up. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP29
[0338] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 106 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI).Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 30. Case CP29PSS (0-10) PIS (0-10) Overall CBPI Baseline i 6.8 8.3 7.5Best response (visit 6 of i 2.2 4.3 3.3 (J. 56%)7)Final i 6.5 7.2 6.8 Variation (baseline — >• i | 0.3 J. 1.1 J. 0.7 (9%)final) iCONCLUSION / COMMENT S
[0339] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0340] The PSS reduced from 6.8 to 6.5 (reduction of 0.3 points); the PIS reduced from 8.3 to 7.2 (reduction of 1.1 points); the Overall CBPI reduced from 7.5 to 6.8, corresponding to a reduction of 9%.
[0341] It should be noted, however, that the above classification stems exclusively from the comparison between the baseline score and the final score. As demonstrated below, this subject came to fully satisfy the criterion of therapeutic success during the period of regular administration of the medicament.
[0342] Analysis of the best response under treatment: in the 6th of 7 evaluations, the subject reached PSS of 2.2, PIS of 4.3 and Overall CBPI of 3.3 — reduction of 56% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 4.6 points in the PSS and of 4.0 points in the PIS).
[0343] The final score, of 6.8, is higher than the best value obtained, which translates to a loss of the therapeutic effect along the follow-up (relapse of 3.5 points in theOverall CBPI). It should be noted that the deterioration followed an interruption of 56 days between applications, greater than the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.
[0344] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result having been lost only following the interruption of the applications. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP30
[0345] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 98 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 31. Case CP30PSS (0-10) PIS (0-10) Overall CBPI Baseline i 5.2 7.5 6.4Best response (visit 4 of i 2.2 2.8 2.5 (J. 60%)7)Final 5.0 6.7 5.8 Variation (baseline — >• 0.2 J. 0.8 J. 0.6 (8%)final) iCONCLUSION / COMMENT S
[0346] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0347] The PSS reduced from 5.2 to 5.0 (reduction of 0.2 points); the PIS reduced from 7.5 to 6.7 (reduction of 0.8 points); the Overall CBPI reduced from 6.4 to 5.8, corresponding to a reduction of 8%.
[0348] It should be noted, however, that the above classification stems exclusively from the comparison between the baseline score and the final score. As demonstrated below, this subject came to fully satisfy the criterion of therapeutic success during the period of regular administration of the medicament.
[0349] Analysis of the best response under treatment: in the 4th of 7 evaluations, the subject reached PSS of 2.2, PIS of 2.8 and Overall CBPI of 2.5 — reduction of 60% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.0 points in the PSS and of 4.7 points in the PIS).
[0350] The final score, of 5.8, is higher than the best value obtained, which translates to a loss of the therapeutic effect along the follow-up (relapses of 3.3 points in the Overall CBPI). It should be noted that the deterioration followed an interruption of 49 days between applications, greater than the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.
[0351] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result having been lost only following the interruption of the applications. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP31
[0352] Clinical synthesis: Canine subject, female, without defined breed. Follow-up of 49 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 32. Case CP31PSS (0-10) PIS (0-10) Overall CBPI Baseline i 5.8 4.2 5.0 Best response (visit 3 of i 2.2 2.2 2.2 (J. 55%)6)Final i 6.5 2.8 4.7 Variation (baseline —>■ | +0.7 J. 1.4 J. 0.3 (6%)final)CONCLUSION / COMMENT S
[0353] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0354] The PSS rose from 5.8 to 6.5 (worsening of 0.7 points); the PIS reduced from 4.2 to 2.8 (reduction of 1.4 points); the Overall CBPI reduced from 5.0 to 4.7, corresponding to a reduction of 6%.
[0355] It should be noted, however, that the above classification stems exclusively from the comparison between the baseline score and the final score. As demonstrated below, this subject came to fully satisfy the criterion of therapeutic success during the period of regular administration of the medicament.
[0356] Analysis of the best response under treatment: in the 3rd of 6 evaluations, the subject reached PSS of 2.2, PIS of 2.2 and Overall CBPI of 2.2 — reduction of 55% in relation to the baseline value. At this point, the operational criterion of therapeutic success was fully satisfied (reduction of 3.6 points in the PSS and of 2.0 points in the PIS).
[0357] The final score, of 4.7, is higher than the best value obtained, which translates to a loss of the therapeutic effect along the follow-up (relapse of 2.5 points in the Overall CBPI).
[0358] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, the result not having been maintained until the end of the follow-up. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP32
[0359] Clinical synthesis: Canine subject, male, Pekingese breed. Follow-up of 56 days, with 8 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 3 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure; 1 joint radiographic examination; 1 joint ultrasonographic examination. Table 33. Case CP32PSS (0-10) PIS (0-10) Overall CBPI Baseline4.88.86.8Best response (coincides i 4.8 8.8 6.8 (no improvement) with the baseline) iFinal i 4.8 8.8 6.8 Variation (baseline —A = 0.0 = 0.0 = 0.0 (no change) final) iCONCLUSION / COMMENT S
[0360] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0361] The PSS remained unchanged at 4.8 (without variation); the PIS remained unchanged at 8.8 (without variation); the Overall CBPI remained unchanged at 6.8.
[0362] As already exposed in this specification, the response to medicaments in veterinary patients — as well as in humans — suffers influence of individual differences of genetics, age, body composition, metabolic rate and drug interactions.Case CP33
[0363] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 97 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 34. Case CP33PSS (0-10) PIS (0-10) >... O....v...e..r.. -a-l-l-- CBPI Baseline i7.59.7Best response (visit 3 of > ,7) I . .. . 9.3 8.4 (| 2%) Final i 7.8 9.5 8.6 Variation (baseline — t +03 1 0.2 = 0.0 (no change) final) iCONCLUSION / COMMENT S
[0364] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0365] The PSS rose from 7.5 to 7.8 (worsening of 0.3 points); the PIS reduced from 9.7 to 9.5 (reduction of 0.2 points); the Overall CBPI remained unchanged at 8.6.
[0366] Among the factors potentially associated with the absence of response in this subject, the extreme baseline severity is registered (Overall CBPI of 8.6, close to the ceiling of the scale).
[0367] As already exposed in this specification, the response to medicaments in veterinary patients — as well as in humans — suffers influence of individual differences of genetics, age, body composition, metabolic rate and drug interactions.
[0368] Analysis of the best response under treatment: in the 3rd of 7 evaluations, the subject reached PSS of 7.5, PIS of 9.3 and Overall CBPI of 8.4 — reduction of 2% in relation to the baseline value.Case CP34
[0369] Clinical synthesis: Canine subject, female, Akita Inu breed. Follow-up of 115 days, with 13 serial evaluations by the Canine Brief Pain Inventory (CBPI). Subject with baseline scores at the ceiling of the scale (PSS 10.0; Overall CBPI 9.8), configuring extreme severity. Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registeredin the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 35. Case CP34PSS (0-10) PIS (0-10) Overall ( BPI Baseline i 10.0 9.7 9.8 Best response (visit 2 of i „ „ „ „ 8.8 (| 11%)13)7'8 9 8Final i 10.0 10.0 10.0 Variation (baselinre — >■ I „ „ . , . , | +0.2 (worsening of . ! = 0.0 | +0.;final) i 2%) CONCLUSION / COMMENT S
[0370] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0371] The PSS remained unchanged at 10.0 (without variation); the PIS rose from 9.7 to 10.0 (worsening of 0.3 points); the Overall CBPI rose from 9.8 to 10.0, corresponding to a worsening of 2%.
[0372] Among the factors potentially associated with the absence of response in this subject, the extreme baseline severity is registered (Overall CBPI of 9.8, close to the ceiling of the scale).
[0373] As already exposed in this specification, the response to medicaments in veterinary patients — as well as in humans — suffers influence of individual differences of genetics, age, body composition, metabolic rate and drug interactions.
[0374] Analysis of the best response under treatment: in the 2nd of 13 evaluations, the subject reached PSS of 7.8, PIS of 9.8 and Overall CBPI of 8.8 — reduction of 11% in relation to the baseline value.
[0375] The final score, of 10.0, is higher than the best value obtained, which translates to a loss of the therapeutic effect along the follow-up (relapse of 1.2 points in the Overall CBPI).Case CP35
[0376] Clinical synthesis: Canine subject, male, without defined breed. Follow-up of 112 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 7 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 36. Case CP35PSS (0-10) PIS (0-10) Overall CBPI Baseline i 7.25.36.3Best response (visit 7 of i 4.8 6.0 5.4 (J. 15%)12)Final5.2 7.7 6.5 Variation (baseline — A J. 2.0 | +2.4 | +0.2 (worsening of final) i 3%) CONCLUSION / COMMENT S
[0377] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0378] The PSS reduced from 7.2 to 5.2 (reduction of 2.0 points); the PIS rose from 5.3 to 7.7 (worsening of 2.4 points); the Overall CBPI rose from 6.3 to 6.5, corresponding to a worsening of 3%.
[0379] As already exposed in this specification, the response to medicaments in veterinary patients — as well as in humans — suffers influence of individual differences of genetics, age, body composition, metabolic rate and drug interactions.
[0380] Analysis of the best response under treatment: at the 7th of 12 evaluations, the subject reached PSS of 4.8, PIS of 6.0 and Overall CBPI of 5.4 — reduction of 15% in relation to the baseline value.
[0381] The final score, of 6.5, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 1.1 points in the Overall CBPI).Case CP36
[0382] Clinical synthesis: Canine subject, female, mixed breed. Follow-up of 222 days, with 12 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 7 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 37. Case CP36PSS (0-10) PIS (0-10) Overall CBPI Baseline i 5.55.85.7Best response (visit 5 of i 4.0 4.3 4.2 (j 26%)12) LFinal i 6.0 6.2 6.1 Variation (baseline —>■ i f +0.5 | +0.4 | +0.4 (worsening of final) 7%) CONCLUSION / COMMENT S
[0383] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0384] The PSS rose from 5.5 to 6.0 (worsening of 0.5 points); the PIS rose from 5.8 to 6.2 (worsening of 0.4 points); the Overall CBPI rose from 5.7 to 6.1, corresponding to a worsening of 7%.
[0385] As already exposed in this specification, the response to medicaments in veterinary patients — as well as in humans — suffers influence of individual differences of genetics, age, body composition, metabolic rate and drug interactions.
[0386] Analysis of the best response under treatment: at the 5th of 12 evaluations, the subject reached PSS of 4.0, PIS of 4.3 and Overall CBPI of 4.2 — reduction of 26% in relation to the baseline value.
[0387] The final score, 6.1, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapses of 1.9 points in the Overall CBPI). It should be noted that the deterioration followed an interruption of 104 days between applications, superior to the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.Case CP37
[0388] Clinical synthesis: Canine subject, male, mixed breed. Follow-up of 49 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 38. Case CP37PSS (0-10) PIS (0-10) Overall CBPIBaseline 3.0 1.7 2.3 Best response (visit 3 of i 3.0 1.3 2.2 (J. 7%)6)Final i 3.0 2.2 2.6 Variation (baseline —> i = 0.0 f +0.5 f +0.3 (worsening of final) 11%) CONCLUSION / COMMENT S
[0389] Case classified as FLOOR EFFECT. The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 2.3), with scores already close to the floor of the scale. In this condition, the arithmetic margin available for demonstrating reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0390] The PSS remained unchanged at 3.0 (no variation); the PIS rose from 1.7 to 2.2 (worsening of 0.5 points); the Overall CBPI rose from 2.3 to 2.6, corresponding to a worsening of 11%.
[0391] Analysis of the best response under treatment: at the 3rd of 6 evaluations, the subject reached PSS of 3.0, PIS of 1.3 and Overall CBPI of 2.2 — reduction of 7% in relation to the baseline value.Case CP38
[0392] Clinical synthesis: Canine subject, female, mixed breed. Follow-up of 35 days, with 5 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 5 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 39. Case CP38PSS (0-10) PIS (0-10) Overall CBPI Baseline i 3.02.02.5Best response (visit 4 of i 2.0 1.8 1.9 (J. 23%)5)Final i3.0 3.0 3.0 Variation (baseline —> i = 0.0 ( +1.0 f +0.5 (worsening of final) 20%) CONCLUSION / COMMENT S
[0393] Case classified as FLOOR EFFECT. The subject presented as oligosymptomatic in the baseline evaluation (Overall CBPI of 2.5), with scores already close to the floor of the scale. In this condition, the arithmetic margin available for demonstrating reduction is intrinsically limited: the operational criterion of success, which requires an absolute drop of at least 2 points in the PIS, cannot be satisfied even if complete normalization of the scores occurs.
[0394] The PSS remained unchanged at 3.0 (no variation); the PIS rose from 2.0 to 3.0 (worsening of 1.0 points); the Overall CBPI rose from 2.5 to 3.0, corresponding to a worsening of 20%.
[0395] Analysis of the best response under treatment: at the 4th of 5 evaluations, the subject reached PSS of 2.0, PIS of 1.8 and Overall CBPI of 1.9 — reduction of 23% in relation to the baseline value.
[0396] The final score, of 3.0, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 1.1 points in the Overall CBPI).Case CP39
[0397] Clinical synthesis: Canine subject, male, mixed breed. Follow-up of 97 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 40. Case CP39PSS (0-10) PIS (0-10) Overall CBPI Baseline i 5.5 6.2 5.8 Best response (visit 3 of 7) i 2.5 6.7 4.6 (J 21%)Final 7.8 7.3 7.6 Variation (baseline ' t f +2.3 f +1.1 f +1.8 (worsening of 29%) final) iCONCLUSION / COMMENT S
[0398] Case classified as EFFICACY DEPENDENT ON TREATMENT, a category characterized by low adherence to the protocol, with documented correlation between adherence and response.
[0399] The PSS rose from 5.5 to 7.8 (worsening of 2.3 points); the PIS rose from 6.2 to 7.3 (worsening of 1.1 points); the Overall CBPI rose from 5.8 to 7.6, corresponding to a worsening of 29%.
[0400] Analysis of the best response under treatment: at the 3rd of 7 evaluations, the subject reached PSS of 2.5, PIS of 6.7 and Overall CBPI of 4.6 — reduction of 21% in relation to the baseline value.
[0401] The final score, of 7.6, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 3.0 points in the Overall CBPI). It should be noted that the deterioration followed an interruption of 42 days between applications, superior to the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.Case CP40
[0402] Clinical synthesis: Canine subject, female, Schnauzer breed. Follow-up of 50 days, with 6 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 6 serial complete blood counts, without alterations of the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 41. Case CP40PSS (0-10) .. P...I..S.. (0-10) Overall CBPI Baseline i3.0Best response (visit 4 of 2.0 5.7 3.8 (| 10%)6) |Final i 5.2 6.0 5.6 Variation (baseline i f +2.2 | +0.5 | +1.4 (worsening of final) i 32%) CONCLUSION / COMMENT S
[0403] Case classified as NON-RESPONSE in the analysis of the baseline-final pair: the net variation at the end of the follow-up does not reach the adopted threshold of clinical relevance (10%).
[0404] The PSS rose from 3.0 to 5.2 (worsening of 2.2 points); the PIS rose from 5.5 to 6.0 (worsening of 0.5 points); the Overall CBPI rose from 4.2 to 5.6, corresponding to a worsening of 32%.
[0405] As already exposed in this specification, the response to medicaments in veterinary patients — as well as in humans — suffers influence of individual differences of genetics, age, body composition, metabolic rate and drug interactions.
[0406] Analysis of the best response under treatment: at the 4th of 6 evaluations, the subject reached PSS of 2.0, PIS of 5.7 and Overall CBPI of 3.8 — reduction of 10% in relation to the baseline value.
[0407] The final score, of 5.6, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 1.8 points in the Overall CBPI).Case CP41
[0408] Clinical synthesis: Canine subject, female, mixed breed. Follow-up of 98 days, with 7 serial evaluations by the Canine Brief Pain Inventory (CBPI). Complementary documentation available: 4 serial complete blood counts, without alterations in the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 42. Case CP41PSS (0-10) PIS (0-10) Overall CBPI Baseline i 5.0 3.7 4.3 Best response (visit 4 of i 0.8 0.7 0.7 (J. 84%)7)Final 8.5 7.3 7.9 Variation (baseline — >• i f +3.5 | +3.6 | +3.6 (worsening of final) i 83%) CONCLUSION / COMMENT S
[0409] Case classified as EFFICACY DEPENDENT ON TREATMENT, a category characterized by low adherence to the protocol, with documented correlation between adherence and response.
[0410] The PSS rose from 5.0 to 8.5 (worsening of 3.5 points); the PIS rose from 3.7 to 7.3 (worsening of 3.6 points); the Overall CBPI rose from 4.3 to 7.9, corresponding to a worsening of 83%.
[0411] This is the paradigmatic case of the relationship between the administration of the medicament and the therapeutic effect. The subject responded in a practically complete manner under regular treatment, reaching an Overall CBPI of 0.7 at the fourth evaluation — a reduction of 84% in relation to the baseline of 4.3 and integral satisfaction of the operational criterion of therapeutic success. There then ensued an interruption of 49 days between applications, after which the scores progressively returned to levels higher than the initial ones (final Overall CBPI of 7.9).
[0412] Analysis of the best response under treatment: at the 4th of 7 evaluations, the subject reached PSS of 0.8, PIS of 0.7 and Overall CBPI of 0.7 — reduction of 84% in relation to the baseline value. At this point, the operational criterion of therapeutic success was integrally satisfied (reduction of 4.2 points in the PSS and of 3.0 points in the PIS).
[0413] The final score, of 7.9, is higher than the best value obtained, which translates to a loss of the therapeutic effect throughout the follow-up (relapse of 7.2 points in the Overall CBPI). It should be registered that the deterioration followed an interruption of 49 days between applications, higher than the weekly interval foreseen in the protocol, which establishes a temporal correlation between the suspension of the medicament and the return of the symptomatology.
[0414] This subject, therefore, demonstrated therapeutic efficacy under regular treatment, having the result been lost only following the interruption of the applications. The analysis restricted to the baseline-final pair underestimates the efficacy effectively demonstrated in this case.Case CP42
[0415] Clinical synthesis: Canine subject, male, Bernese Mountain Dog breed. Follow-up of 114 days, with 10 serial evaluations by the Canine Brief Pain Inventory (CBPI). It is a breed with recognized predisposition to early articular and neoplastic diseases. Low adherence to the protocol was registered (33%), due to two interruptions of the medicament greater than 14 days (15 and 22 days).Complementary documentation available: 7 serial complete blood counts, without alterations in the hematological series, suggesting absence of toxicity of the present disclosure. There is no radiographic report registered in the database for this subject; the diagnosis of osteoarthritis was established by clinical examination and history of the animal.Table 43. Case CP42PSS (0-10) PIS (0-10) Overall CBPI Baseline i 2.2 1.0 1.6 Best response (coincides i 2.2 1.0 1.6 (no improvement) with the baseline)Final i 7.5 6.3 6.9 Variation (baseline —> i f +5.3 f +5.3 f +5.3 (worsening of final) 326%) CONCLUSION / COMMENT S
[0416] Case classified as EFFICACY DEPENDENT ON TREATMENT, a category characterized by low adherence to the protocol, with documented correlation between adherence and response.
[0417] The PSS rose from 2.2 to 7.5 (worsening of 5.3 points); the PIS rose from 1.0 to 6.3 (worsening of 5.3 points); the Overall CBPI rose from 1.6 to 6.9, corresponding to a worsening of 326%.
[0418] It should be clarified, in attention to the rigor of the data, that this subject entered the protocol already oligosymptomatic (baseline Overall CBPI of 1.6) and that the best score registered by it throughout the entire follow-up was the baseline value itself: there was, therefore, no measurable improvement by the CBPI. The case documents the progressive deterioration up to an Overall CBPI of 6.9 associated with the two interruptions of the treatment greater than 14 days (15 and 22 days), with a global adherence of only 33%, and serves as a demonstration that the suspension of the medicament is accompanied by a worsening of the articular condition.LOSS OF EFFECT DUE TO DISCONTINUATION: EVIDENCE OF CAUSAL RELATIONSHIP
[0419] The analysis of the individual trajectory of the CBPI scores, evaluation by evaluation, reveals a pattern of high probative value regarding the existence of a real pharmacological effect of the present disclosure: in the subjects in which there was an interruption of the applications for a period greater than 14 days, the previously obtained clinical improvement was progressively lost, with a return of the painful symptomatology and of the functional limitation.
[0420] This phenomenon — designated in the pharmacological literature as loss of effect due to discontinuation (dechallenge) — constitutes evidence of causality of a higher order than mere association: if the observed improvement resulted from evaluator bias, from a placebo effect on the part of the owner, or from spontaneous fluctuation of the disease, there would be no reason for the deterioration to correlate temporally, and in a consistent manner, with the suspension of the applications of the medicament.
[0421] Methodological note: The intervals between applications were measured from the dates of the serial evaluations of the CBPI, which accompany the weekly administration calendar of the protocol. The same threshold used in the monitoring of adherence of the study — an interval greater than 14 days — was adopted to characterize the interruption. The consistency of the method is confirmed by subject CP42, whose adherence monitoring platform registered two pauses of 15 and 22 days, exactly coinciding with the two interruptions ascertained by this criterion.
[0422] The table below consolidates the subjects that presented a relapse of at least 1.0 point in the Overall CBPI following an interruption of the protocol greater than 14 days:Table 44. Relapses„ Best res ,ponseTInt .erruption „ ,, , Case Baseline CBPI under ,, Final CBPI Relapse t .reatment (day 's)CP41 4.30.7 Q 84%)49 7.9+7.2CP42 1.6 1.6 (1 0%) 22 6.9 +5.3 CP29 7.5 3.3 (1 56%) 56 6.8 +3.5 CP30 6.4 2.5 (1 60%) 49 5.8 +3.3 CP39 5.8 4.6 (1 21%) 42 7.6 +3.0 CP36 5.7 4.2 (1 26%) 104 6.1 +1.9 CP25 2.0 0.3 (1 84%) 50 1.5 +1.2 CP214.9 2.4 (1 51%) 19 3.5 +1.0
[0423] It should be highlighted that 9 of the 42 subjects of the cohort (CP 19, CP21, CP24, CP25, CP28, CP29, CP30, CP31, CP41) managed to integrally satisfy the operational criterion of therapeutic success during the period of regular administration of the medicament, coming to lose this condition in the course of the follow-up. In 5 of them (CP21, CP25, CP29, CP30, CP41), the loss of the effect followed documented interruptions of the applications greater than 14 days, according to the table above. In the others (CPI 9, CP24, CP28, CP31), there is no registered interruption, with the effect having declined throughout the follow-up — which is compatible with the chronic nature of the disease and with the need for maintenance of the treatment.
[0424] For this reason, the success rate ascertained exclusively by the comparison between the baseline and final scores (33.3%) underestimates the efficacy demonstrated by the present disclosure, which reaches 54.8% when measured by the best response obtained while the animal was under regular administration of the medicament.
[0425] From the whole, furthermore, a teaching of a practical order is extracted regarding the use of the present disclosure: the therapeutic effect depends on the continuity of the administration, being recommendable, in arthritis and in arthrosis — diseases of a chronic nature — , the maintenance of the treatment, as demonstrated, in the inverse sense, by subject CPI 8, which maintained the benefit throughout 421 days of continued use, without loss of efficacy and without cumulative toxicity.CONCLUSION / COMMENT S
[0426] Case that evidences the dependence on the continuous use of the medicament for a good therapeutic effect. A low adherence to the treatment is noted due to two interruptions greater than 14 days (15 and 22 days).
[0427] Response pattern characteristic of therapeutic discontinuation: baseline CBPI 1.6 (oligosymptomatic), improvement during treatment and progressive deterioration to final CBPI 6.9 after the two pauses without use of the present disclosure.
[0428] Complementary observation: If the clinical effect observed in the other subjects were attributable to owner bias or spontaneous fluctuation, there would be no strict temporal correlation between adherence and improvement, nor progressive deterioration after discontinuation. The pattern documented here is compatible exclusively with a real pharmacological effect, by the use of the present disclosure, in this case, loss of effect due to discontinuation of use.
[0429] Safety of the present disclosure:
[0430] Throughout the entire study period, no measurable or harmful side effects were observed in the following parameters:
[0431] Hematological parameters remained within the normal reference values.
[0432] Hepatic and renal function remained unaltered.
[0433] No adverse behavioral alterations were observed.
[0434] No local reactions were observed at the injection sites.
[0435] No animal was withdrawn from the study due to adverse effects.CONCLUSIONS
[0436] The set of quantitative evidences of the experimental data of this experiment elaborated to evaluate the practical use of the present disclosure, whether of the 8 cases above and also of the total of the 42 animals involved, allows the conclusion that the improvement observed in the functional and laboratory parameters associated with arthritis and arthrosis does not constitute spontaneous fluctuation of the diseaseor chance, but a therapeutic response attributable to the therapeutic intervention, that is, to the use of the present disclosure.IMAGING EXAMINATIONS - X-RAY
[0437] All the animals, besides the physical examination, possess a confirmatory radiographic examination (X-ray) for the detection of arthritis and / or arthrosis.
[0438] None of the animals involved in the study showed radiographic signs suggestive of an alteration of worsening in the state of the joint pathology in the X-ray examinations in relation to the radiographic examinations performed at the beginning of the study.
[0439] Although the study has been of short duration, this result reinforces the positive result of the study of the effect of the medicament on the pain level (PSS) and on the interference of pain in the activities of the animal (PIS).IMAGING EXAMINATIONS - ULTRASONOGRAPHY (US)
[0440] A relevant result in this type of imaging (US) was shown by the absence of detectable synovial effusion in the articulations of the majority of the animals at the end of the protocol and also regression of the synovial effusion in the articulations of several animals that presented it at the beginning of the protocol, which is compatible with a positive action of the medicament of the present disclosure on the mechanisms involved in the joint inflammatory process.PRACTICAL EXAMPLE OF THE PRESENT DISCLOSURE - CLINICAL STUDY IN HUMAN BEINGS
[0441] Study Synopsis: This is a prospective, open-label clinical study, without a placebo arm, with longitudinal evaluation of human patients suffering from arthritis, comprising osteoarthritis, rheumatoid arthritis and psoriatic arthritis, treated with the compound of the present disclosure, that is, a medicament using as active ingredient the polymeric (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium).
[0442] The cohort of this clinical trial is composed of 18 (eighteen) patients, distributed as follows: 9 (nine) suffering from osteoarthritis, 8 (eight) suffering from rheumatoid arthritis and 1 (one) patient suffering from psoriatic arthritis with associated cutaneous manifestations, the latter constituting a case of therapeutic substitution by the present disclosure used in a patient with documented intolerance to a first-choice treatment, that is, Methotrexate.
[0443] This example of practical use of the medicament is presented in this specification for explanatory purposes without at any time intending to restrict the scope and utility of the present disclosure.
[0444] Inclusion criteria:— Age between 45 and 75 years— Clinical diagnosis— Clinical imaging diagnosis (X-ray) confirmatory of osteoarthritis, inflammatory markers and clinical examinations for rheumatoid arthritis or psoriatic arthritis— Persistent joint pain for a period equal to or greater than 6 months — Pain score > 4 on the Brief Pain Inventory at baseline evaluation — Documented availability for follow-up of at least 8 weeks
[0445] Exclusion criteria:— Pregnancy or lactation— Active autoimmune diseases (with the exception of rheumatoid arthritis and psoriatic arthritis)— Use of immunosuppressants in the 3 months prior to inclusion— Active infections or history of recurrent infections— Hepatic or renal dysfunction of clinical relevance— Participation in other clinical studies in the previous 6 months
[0446] Treatment Protocol: Each patient received 25 mg of the new medicament, which is the object of the present disclosure intramuscularly, formulated in 3 ml (milliliters) of sterile physiological saline (NaCl 0.9%) once a week, for 4 consecutive weeks. The dose was based on the results of the preclinical canine study, adjusted for average human body weight.
[0447] Evaluations performed:— Brief Pain Inventory (BPI) applied weekly— Short Form 36 (SF-36) applied at baseline evaluation and at the end of the treatmentWeekly medical clinical evaluation— Serial laboratory tests (blood count, complete biochemistry, inflammatory markers)— Continuous monitoring of adverse events
[0448] Evaluation instruments usedBPI QUESTIONNAIRE - BRIEF PAIN INVENTORY
[0449] The Brief Pain Inventory (BPI) or breve inventario da dor in its translation is a standardized instrument, developed by Cleeland and collaborators, validated for measuring chronic pain in human patients on a numerical scale from 0 to 10.
[0450] It comprises two sets of items:• Pain Severity (pain intensity at different moments) and• Pain Interference (functional impact of pain on usual activities)Table 45. Evaluations performedBlock Domains ItemsPain at its best: Average pain:PAIN (Pain Severity)Current pain 3 items ■ scale 0- 10 INTERFERENCE (Pain General activity; Mood; Walking;Work; Relationships; Sleep; 7 items ■ scale 0-10 Interference) Enjoyment of life
[0451] Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) - SF-36 Instrument — Short Form 36
[0452] The Medical Outcomes Study 36- (Short-Form Health Survey (SF-36) is an instrument constructed in the form of a questionnaire for evaluating health-related quality of life, widely validated in multiple clinical and cultural contexts. Composed of 36 items grouped into 8 dimensions, summarized into two main components:— MCS — Mental Component Summary - — Vitality (VT) •— Social functioning (SF)— Role limitations due to emotional problems (RE) Mental health (MH) 0-100Table 46. Evaluations performedComponent Integrating dimensions Range Physical functioning (PF) RolePCS — Physical Component limitations due to physical health 0-100 Summary (RP) Bodily pain (BP) Generalhealth (GH )Vitality (VT) Social functioningMCS — Mental Component (SF) Role limitations due to 0-100 Summary emotional problems (RE) Mentalhealth (MH)
[0453] Evaluations Performed in the human study:
[0454] Brief Pain Inventory (BPI) > applied weekly
[0455] - SF-36 Instrument — Short Form 36 > applied at the beginning and end of the protocol
[0456] - Weekly medical clinical evaluation
[0457] - Laboratory tests (blood count, biochemistry, inflammatory markers) throughout the study
[0458] - Continuous monitoring of adverse eventsRESULTS - BRIEF PAIN INVENTORY:
[0459] The results of the set of 18 patients calculated in an aggregated manner demonstrated a significant improvement in the pain level (54%) comparable to those observed in the canine study, being summarized below:Table 47. Results of the setDomain (scale 0-10) Baseline Final Variation P Pain at its best 4.1 ± 0.8 1.9 ± 0.6 -2.2 (-54%) 0.001 Average pain 5.9 ± 0.9 2.8 ± 1.0 -3.1 (-53%) 0.001 Current pain 5.4 - 1.0 2.5 ± 0.8 -2.9 (-54%) 0.001 AVERAGE REDUCTION OF PAIN SCORES BY THE BPI
[0460] The percentage results of the set of 18 patients evaluated by the BPI were 54%, which exceeds the threshold of 50% to be considered a substantial reduction in pain levels, by the use of the present disclosure.
[0461] Safety in the Human Study: Throughout the study and follow-up period, no measurable or harmful side effects were observed:
[0462] - Laboratory tests remained within normal reference values.
[0463] -No adverse events related to the treatment were reported
[0464] - Absence of significant local reactions at the injection site
[0465] -No patient discontinued the treatment due to adverse effects
[0466] - Follow-up of 4 weeks post-treatment confirmed maintenance of laboratory and clinical parameters within normality criteria.Table 48. SF-36 - TABLE OF ACRONYMS AND ABBREVIATIONSAcronym Dimension No. items What it measures Capacity to perforin physical activities PF Physical Functioning (walking, climbing stairs, bending, earn ingweight)Impact of physical RP Role-Physicalhealth on work and social role BP Bodily Pain Pain intensity and itsinterference in activities Subjective perception of GH General Healthone's own health Energy level versus VT Vitalitytiredness / fatigue SF Social FunctioningImpact of health on social activities Impact of emotional RE Role-Emotional problems on work andsocial role Psychological wellMH Mental Health 5 being, mood and general mental health
[0467] SF-36 Instrument — Short Form 36 - DESCRIPTION
[0468] The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is a generic instrument for evaluating health-related quality of life, widely validated in multiple clinical and cultural contexts. Composed of 36 items grouped into 8 dimensions, summarized into two main components:Table 49. Medical Outcomes Study 36Component Integrating dimensions Range Physical functioning (PF) ■ RolePCS — Physical Component limitations due to physical health 0-100 Summary (RP) Bodily pain (BP) Generalhealth (GH )Vitality (VT) • Social functioningMCS — Mental Component (SF) ■ Role limitations due to 0-100 Summary emotional problems (RE) ■Mental health (MH)
[0469] Scores of the SF-36 questionnaire range from 0 to 100, wherein higher values indicate a better perceived health state. The normalized population average is situated at 50 for both the PCS and MCS components in reference populations adjusted for age and sex.
[0470] The SF-36 complements the BPI by measuring not only pain, but the global impact on the health state perceived by the patient.
[0471] Statistical analysis used: Quantitative variables were presented as mean ± standard deviation. Intra-subject variations (baseline vs. final) were evaluated by the paired t-test, complemented by the Wilcoxon signed-rank test.
[0472] A bilateral significance level of a = 0.05 was adopted. Percentage reductions > 30% in pain scores were considered clinically significant; reductions > 50%, substantial.PRACTICAL USE OF THE PRESENT DISCLOSURE
[0473] The results of the use of the present disclosure in 18 human patients presented below for more in-depth discussion in this specification.
[0474] Patient Pl — Psoriatic Arthritis (PsA) • 58 years -
[0475] Treatment of psoriatic arthritis with the new medicament
[0476] This patient of the study (Patient Pl) presented psoriatic arthritis (PsA), a systemic inflammatory disease usually associated with deformities and joint destruction in approximately 40-60% of patients. Since the prevalence of psoriasis is 2-3% and PsA occurs in about one third of patients with psoriasis, it is a common disease (Gladman DD et al. 2005).
[0477] Patients with PsA can present joint destruction, functional impairment, reduction in quality of life and psychosocial disability to a degree comparable to that of patients with rheumatoid arthritis (RA) (Kang EJ & Kavanaugh A, 2015).
[0478] Treatment with non-steroidal anti-inflammatory drugs, corticosteroids and disease-modifying antirheumatic drugs (DMARDs), such as Methotrexate, are the treatments of choice for this pathology, and in the prior art biological medicaments have been introduced for immunomodulatory action, with positive results (Kang EJ and Kavanaugh A, 2015).
[0479] In the specific case of the patient participating in the clinical trial and suffering from psoriatic arthritis, this patient was absolutely contraindicated for continued use of Methotrexate due to the emergence of severe hepatic toxicity, which forced the abandonment of this treatment.
[0480] After a detoxification period, the patient was admitted to the clinical trial using the same dosage regimen as the other participants, that is, 25 mg weekly of the compound of the present disclosure for 4 weeks intramuscularly.
[0481] Result: The patient presented a favorable evolution with the almost complete elimination of psoriasis lesions on the hands and feet, accompanied by strong symptomatic relief in joint pain and in quality of life, evaluated by the BPI and SF 36 made available in the table below and in the Annex.Table 50. Patient Pl — Psoriatic Arthritis (PsA) • 58 years - BPI Pain (0-10) BPT I inntieerrfwerreennccee ( u0,-SF_36 pcs(0.100) SF-36MCS(0-100) Basel inc 6.2 7.1 28 35 Final (4 weeks) 1.5 2.0 52 56 Variation (baseline
[0482] The clinical result considered exceptional, in the cutaneous lesions and in the levels of pain (BPI) and well-being (SF 36), although limited to one case, indicates that the action of the medicament formulated with the active ingredient of the medicament, which is the object of the present disclosure, is due to its immunomodulatory action, since psoriatic arthritis, like rheumatoid arthritis, is an autoimmune disease.
[0483] No adverse effect was noted with the use of the present disclosure, also in this case, which additionally indicates that the present disclosure can be used in the substitution of traditional medicament in the case of the emergence of side effects preventing the continuity of the first-choice medicament in the current prior art, which are usually the disease-modifying antirheumatic drugs (DMARDs), whose most used representative as first choice is the medicament named Methotrexate (CAS • 59-05-2; ATC • L01BA0), which was previously used by this specific patient.
[0484] Patient P2 — Osteoarthritis (OA) • 62 years • F
[0485] Clinical aspects: Bilateral involvement of tibiofemoral joints, with chronic pain of evolution greater than five years. Clinically perceptible functional response identified already in the second week of treatment. Without alterations in hepatic or renal parameters.
[0486] Result: patient presented improvement in all aspects with expressive decrease in pain scores (BPI) and improvement in quality of life (SF 36).Table 51. Patient P2 — Osteoarthritis (OA) • 62 years • FSF-36 PCS (fl- SF-36 MCS (fl- BPI Pain (0-10) BPI Interference (0-10) 100) 100) Baseline 41 Final (4 weeks) 49 Variation (baseline| 3.7 (51%) final) |||lti+17|||| Table 52. Patient P3 — Osteoarthritis (OA) • 68 years • MBPI Interference SF-36 PCS (fl- SF-36 MCS (fl- BPI Pain (0-10)(0-10) 100) 100) Baseline 5.8 6.5 30 39 Final (4 weeks) 2.5 2.7 50 54 Variation (baseline 1 3.3 (57%) J 3.8 (58%) f +20 final)
[0487] Clinical aspects: Right coxofemoral OA confirmed radiographically Prolonged prior use of non-steroidal anti-inflammatory drugs (NSAIDs) with limiting gastrointestinal manifestations. Treatment with the present disclosure without inter currences as well as with partial resumption of activities.
[0488] Result: The patient presented improvement in all aspects with an expressive decrease in pain scores (BPI) and improvement in quality of life (SF 36) with partial resumption of daily activities.Table 53. Patient P4 — Osteoarthritis (OA) 55 years - FSF-36 PCS (fl- SF-36 MCS (fl- BPI Pain (0-10) BPI Interference(0-10) 100) 100) Baseline 5.5 6.3 34 42 Final (4 weeks) ) 22 2.556 Variation (baselineI 3.3 (60%) I 3.8 (60%) t +19 t +14
[0489] Clinical aspects: Polyarticular involvement of mild to moderate intensity. Marked improvement in range of motion and in ambulation capacity.
[0490] Result: The patient presented improvement in all aspects with an expressive decrease in pain scores (BPI) and improvement in quality of life (SF 36) with improvement in movement capacity and consequent improvement in psychological aspects.Table 54. Patient P5 — Osteoarthritis (OA) 71 years - MBPI Pain (0-10) BPI Interference SF-36 PCS (fl- SF-36 MCS (fl- (0-10) 100) 100) Baseline 6.0 7.0 28 38 Final (4 weeks) 2.8 3.2 47 52 Variation (baseline J. 3.2 (53%) 1 3.8 (54%) f +19 ) +14 final)
[0491] Clinical aspects: OA of the cervical and lumbar spine associated with mild foraminal stenosis. Partial resumption of work activities during the follow-up.
[0492] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36) with partial improvement in movement capacity and work activities and consequent improvement in psychological aspects.Table 55. Patient P6 — Osteoarthritis (OA) • 60 years •BPI Interference SF-36 PCS (fl- SF-36 MCS (fl- BPI Pain (0-10)(0-10) 100) 100) Baseline 6.8 26 36 Final (4 weeks) 3.8 46 50 Variation (baseline J. 3.7 (49%) t +20 ' final)
[0493] Clinical aspects: Bilateral tibiofemoral involvement. Patient with associated comorbidity: systemic arterial hypertension under the use of control medicament. No adverse pharmacological or clinical interference was noted between the treatment with the present disclosure and the antihypertensive medicament.
[0494] Result: The patient presented improvement in all aspects with a good decrease in pain scores (BPI) and reasonable improvement in quality of life (SF 36) with recovery of the capacity for work activities and consequent improvement in psychological aspects.Table 56. Patient P7 — Osteoarthritis (OA) • 66 years • MSF-36 PCS (fl- SF-36 MCS (fl- BPI Pain (0-10) BPI Interference (0-10) 100) 100) Baseline 6.2 43 Final (4 weeks) 2.0 2.3 54 57 Variation (baseline|||1|| final)
[0495] Clinical aspects: OA of the phalangeal and carpal joints.
[0496] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and reasonable improvement in quality of life (SF 36). Consequently, [the patient] presented expressive recovery of manual dexterity and fine object manipulation capacity.Table 57. Patient P8 — Osteoarthritis (OA) • 72 years • FBPI Interference SF-36 PCS (fl- SF-36 MCS (fl- BPI Pain (0-10)(0-10) 100) 100) Baseline 6.2 7.1 25 34 Final (4 weeks) 2.7 3.0 45 50 Variation (baselineJ. 3.5 (56%) ( 4.1 (58%) T +20 ( +16 final)
[0497] Clinical aspects: Advanced polyarticular OA with negative reflexes on sleep quality and sociability.
[0498] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and reasonable improvement in quality of life (SF 36). Additionally, [the patient] presented significant improvement in sleep quality and in sociability. Table 58. Patient P9 — Osteoarthritis (OA) 58 years - FBPI Pain (0-10) BPI Interference SF-36 PCS (fl- SF-36 MCS (fl- (0-10) 100) 100) Baseline6.5 44 Final (4 weeks) 2.3 2.6 55 58 Variation (baseline 1 3.4 (60%) ( 3.9 (60%) ( +20 ( +14 final)
[0499] Clinical aspect: Tibiofemoral OA in initial phase. Maintained light aerobic physical activity during the protocol, without symptomatic exacerbation.
[0500] Result: Despite the OA in initial stage, the patient presented improvement in all aspects with a decrease in pain scores (BPI) and reported improvement in quality of life (SF 36).Table 59. Patient P10 — Osteoarthritis (OA) 64 years - MBPI Interference SF-36 PCS (0- SF-36 MCS (0- BPI Pam (0-10)Baseline 6.06.8 3140 Final (4 weeks) 2.5 2.8 51 55 Variation (baseline( 3.5 (58%) ( 4.0 (59%) ( +20 ( +15 —>■ final)
[0501] Clinical aspect: The patient presents coxofemoral and tibiofemoral OA with a report of strong interference in the sleep pattern due to an effect derived from continuous pain.
[0502] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and reasonable improvement in quality of life (SF 36). Additionally, [the patient] presented significant improvement in sleep quality, reporting an expressive reduction in nocturnal pain, with normalization of the sleep pattern.Table 60. Patient Pl 1 — Rheumatoid Arthritis (RA) • 52 years • FBPI Interference SF-36 PCS (0- SF-36 MCS (0- BPI Pam (0-10)(0.10) 100)100) Baseline 6.3 7.0 27 37 Final (4 weeks) 3.0 3.2 47 51 Variation (baseline | 3.3 (52%) J 3.8 (54%) f +20 ) +14—> final)
[0503] Clinical aspect: Presented seropositive RA, with an evolution of eight years. Refractory to methotrexate used as monotherapy on dates prior to the experiment.
[0504] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36). Marked reduction in articular morning stiffness during the protocol of use of the present disclosure.Table 61. Patient P12 — Rheumatoid Arthritis (RA) 59 years - FSF-36 PCS (fl- SF-36 MCS (fl- B oPmI P nai •n (0-10) BPI Interference100) 100) Baseline . 5 8 6.5. 30 . 39. Final (4 weeks) 2.8 3.0 50 53 Variation (baseline 1 3.0 (52%) 1 3.5 (54%) f +20 t +14—>■ final)
[0505] Clinical aspect: RA of moderate activity with altered inflammatory markers.
[0506] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36) with a reduction in the number of tender joints (TJC) from 8 to 3. The inflammatory markers (ESR, CRP) showed to be normalized at the end of the follow-up.Table 62. Patient P13 — Rheumatoid Arthritis (RA) • 63 years • MBPI Pam (0-10) BPI Interference SF-36 PCS (0- SF-36 MCS (0- Baseline6.57.226 36 Final (4 weeks) 3.2 3.5 46 50 Variation (baselineJ. 3.3 (51%) J. 3.7 (51%) f +20 f +14 —>■ final)
[0507] Clinical aspect: Seropositive RA, elevated quantitative rheumatoid factor.
[0508] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36). Additionally, the patient presented a perceptible decrease in synovial edema in the left leg upon clinical palpation. The inflammatory marker showed to be decreased at the end of the followup.Table 63. Patient P14 — Rheumatoid Arthritis (RA) 56 years - FBPI Interference (0- BPI Pain (0-10)1ftV SF-36PCS(0-100) S F-36 MCS (0-100) Baseline 5.5 6.3 32 41 Final (4 weeks) 2.5 2.7 52 55 Variation (baseline4 3.0 (55%) 4 3.6 (57%) | +20 f +14 —> final)
[0509] Clinical aspect: RA of recent onset (less than 24 months).
[0510] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36). Good functional response.Table 64. Patient Pl 5 — Rheumatoid Arthritis (RA) 67 yearsBPI Interference SF-36 PCS (0- SF-36 MCS (0- BPI Pam (0-10)Baseline 6.0 6.8 28 37 Final (4 weeks) 2.9 3.1 48 57 Variation (baseline4 3.1 (52%) 4 3.7 (54%) f +20 4 +20 —>■ final)
[0511] Clinical aspect; RA of long duration (15 years). Reports previous use of leflunomide with mild hepatic adverse manifestations that motivated prior discontinuation 3 months before the start of the protocol.
[0512] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36). Hepatic examinations with unaltered values with the use of the present disclosure.Table 65. Patient P16 — Rheumatoid Arthritis (RA) • 67 years • FB ..P..I. P..am (0-10) BPI Interference SF-36 PCS (0- SF-36 MCS (0-Baseline 6.06.8 2837 Final (4 weeks)2.9 3.1 48 51 Variation (baseline( 3.1 (52%) ( 3.7 (54%) ( +20 ( +14 —>■ final)
[0513] Clinical aspect: RA characterized clinically despite being seronegative, with involvement of wrist and ankle joints.
[0514] Result: The patient showed improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36).Table 66. Patient P17 — Rheumatoid Arthritis (RA) • 61 years • FBPI Pain (0-10) BPI Interference SF-36 PCS (0- SF-36 MCS (0- (0-10) 100) 100)Baseline 6.2 7.0 29 38 Final (4 weeks) 3.0 3.3 49 52 Variation (baseline ( 3.2 (52%) ( 3.7 (53%) ( +20 ( +14 —>■ final)
[0515] Clinical aspect: Moderate active RA, in joint follow-up with the rheumatology specialty.
[0516] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36). Treatment with the present disclosure conducted in addition to the current rheumatological regimen with the use of non-steroidal analgesics (Meloxicam) without negative drug interactions observed.Table 67. Patient Pl 8 — Rheumatoid Arthritis (RA) • 54 years •..... .. BPI Interference SF-36 PCS (0- SF-36 MCS (0- BPI Pam (0-10)Baseline 5.96.7 3039 Final (4 weeks)2.8 3.0 50 53 Variation (baseline( 3.1 (53%) ( 3.7 (55%) ( +20 ( +14 — final)
[0517] Clinical aspect: Symmetrical polyarticular RA with considerable physical impairment and elevated baseline inflammatory markers (CRP and ESR).
[0518] Result: The patient presented improvement in all aspects with a decrease in pain scores (BPI) and improvement in quality of life (SF 36), CRP and ESR, with documented normalization after the fourth week of treatment with the medicament that is the object of the present disclosure.CONCLUSION
[0519] The results of the present study demonstrate, in a cohort of 18 human patients suffering from three distinct clinical forms of arthritis, statistically significant and clinically relevant improvement in all domains of pain and functional interference evaluated by the Brief Pain Inventory. The mean reductions were situated at 54% in the pain domains and at 55-59% in the seven interference domains, with p < 0.001 in all comparisons.
[0520] Additionally, the application of Short Form 36 evidenced substantial elevations in the physical (PCS) and mental (MCS) summary components, with an approximation to the normalized population mean values, translating multidimensional recovery of the health status perceived by the patients.
[0521] The safety profile was characterized by the complete absence of adverse events imputable to the experimental treatment, with stability of laboratory parameters and absence of local reactions. Such a profile contrasts favorably with that of conventional disease-modifying antirheumatic drugs (DMARDs), known for their hepatic, hematological, and gastrointestinal toxicity — a limitation illustrated by the emblematic case Pl, a patient with PsA intolerant to methotrexate due to severe hepatotoxicity, who presented a complete response to the experimental protocol without any important adverse event reported.
[0522] The direct correlation between the results presented herein and those obtained in a parallel study in a canine cohort with osteoarthritis strengthens the translational validation of the compound, given that the BPI (human) and CBPI (canine)instruments constitute an equivalent methodological family, allowing direct comparison between species.CORRELATION BETWEEN THE RESULTS OF THE EFFECT OF THE PRESENT DISCLOSURE IN THE ANIMAL MODEL AND IN HUMAN BEINGS
[0523] For this comparison between the results of the studies in dogs and in human beings, the results of the Canine Brief Pain Inventory (CBPI) and of the Brief Pain Inventory (BPI) were analyzed in a comparative manner. The Brief Pain Inventory (BPI) is a standardized evaluation tool developed to measure chronic pain in human patients. The Canine Brief Pain Inventory (CBPI) is an adaptation of the same tool used in human beings, validated specifically for dogs, permitting owners and veterinarians to objectively quantify the pain levels of the animal and its response to treatment. Both versions use a standard numerical rating scale of 0 to 10. This direct correlation is possible because the measurement questionnaires used in dogs (CBPI) are derived from the questionnaires used in humans (BPI).
[0524] Magnitude of the effect: the percentage reduction in the pain scores was comparable between species. In dogs, an average reduction of 58% in the pain scores was observed relative to the time of response. In humans, an average reduction of 54% in the pain scores was observed relative to the time of response. Both studies demonstrated the onset of clinical improvement in the first week of treatment, with a maximum effect observed in the fourth week.
[0525] The direct comparison between the results obtained in the canine and human studies reveals a good correlation, validating the translational relevance of the canine experimental model for use in humans and the efficacy of the established dosage protocol, as well as the therapeutic effect of the present disclosure.
[0526] Safety profile: the absence of measurable side effects was consistent between species, validating the exceptional safety profile of the medicament formulated withthe active ingredient (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) in the established dosage protocol.
[0527] Sustainability of the effects: in both studies, the therapeutic benefits of the present disclosure were maintained during the post-treatment follow-up period, translating to sustained symptomatic relief, accompanied by an absence of documented radiographic progression. The immunomodulator comprising the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium may be formulated as a medicament for injectable use utilizing a sterile suspension of 0.9% NaCl, as reported in this specification, including examples of practical use, without such examples being intended at any time to limit the scope of the present disclosure.MODE OF MANUFACTURE, REPRODUCTION AND FIEED OF APPEICATION
[0528] For the manufacture of the active ingredient, namely the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium, now used in an innovative manner as a pharmaceutical input for the manufacture of medicaments for the treatment of arthritis and arthrosis, all necessary information is available in the prior art, notably in PI 0801803-0; US 8,889,153 B2; US 9,295,682 B2; and EP 2259799 Bl. The manufacture of the pharmaceutical input does not present any difficulty for its reproducibility at any time by a person of ordinary skill in the art, nor for its manufacture on an industrial scale.
[0529] The production method of the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) used for the purposes of the present disclosure is likewise contained and reported in the prior art in PI 0305373-3 and US 10 / 978,683, and comprises essentially the utilization of the fungus Aspergillus oryzae (A. oryzae) in an appropriate medium for the production of the immunomodulatory compound. Without the need for additional information, any person of ordinary skill in the art, with the aid solely of the information andexplanations contained herein, is enabled to understand, reproduce and use the present disclosure to its full extent.
[0530] The present disclosure has broad applicability in the treatment of various forms of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, idiopathic arthritis, gouty arthritis, infectious arthritis, and other inflammatory joint conditions, including arthrosis. The treatment may be used as monotherapy or in combination with other therapeutic agents, such as traditional anti-inflammatory drugs, diseasemodifying antirheumatic drugs (DMARDs), corticosteroids, and biological therapies, offering flexibility in the clinical management of arthritis and arthrosis in all their clinical manifestations or forms.
[0531] The present disclosure is particularly valuable for all human patients suffering from arthritis in all its clinical presentations and from arthrosis, including those who do not respond adequately to conventional treatments, patients with contraindications to traditional anti-inflammatory drugs, DMARDs, corticosteroids, or biological therapies, and patients who develop unacceptable side effects with existing therapies. In the event of the emergence of side effects preventing the use of a first-choice medicament, the present disclosure may be used in its substitution, as indicated in this specification and demonstrated by the example of practical use. In veterinary medicine, the present disclosure offers a safe alternative for the long-term treatment of arthritis and arthrosis, including animals that do not respond adequately to conventional treatments and animals that develop unacceptable side effects with existing therapies.
[0532] The active substance, namely the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium), may be presented or supplied for use either separately and formulated for injectable application, or associated in the form of conjugated parts in a solid-diluent form, when possible or desirable; and also in the form of solid forms or solutions, in microencapsulated pharmaceutical forms, in liposomes, or in separate systems for administration, andfinally in injectable pharmaceutical forms and oral formulations. For the preparation of a simple administration form, the immunomodulator used as the active ingredient of medicaments may be prepared for administration with the utilization of any aqueous solutions known in the art, or optionally utilizing excipients, suspensions, carriers, and / or stabilizing substances known in the art.DOSAGES, DOSAGE REGIMEN AND TREATMENT SCHEMES — FIXED COMPONENT AND VARIABLE COMPONENTS
[0533] The quantitative dosages of the medicaments, the dosage regimen, and other aspects related to their practical use may be freely established and fixed, at any time, in a wide series of combinations and variations that occur in medical or veterinary practice empirically, depending on the specific case and the clinical conditions of the patients to be treated, whether human or animal. These parameters linked to the practical use of the present disclosure may and should be subject to quantitative and qualitative adjustments and modifications according to the case and pathology to be treated, at any time, in human beings and animals, without this implying or signifying any change in the nature, utility, or scope of the present disclosure.
[0534] The active ingredients, namely the immunomodulator (polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium) and, additionally, another substance that also possesses therapeutic activity in arthritis and arthrosis — which may be selected from the group of chemical substances such as analgesics, nonsteroidal anti-inflammatory drugs, DMARDs, corticosteroids, and biological therapies, in a non-exhaustive enumeration — may be administered in medical practice combined with the active ingredient, jointly, simultaneously, consecutively, or sequentially, by any pharmacologically appropriate route.
[0535] The present disclosure is susceptible to reproduction and industrial manufacture with only the information contained in this specification, by any person of ordinary skill in the art, without difficulty. Any animal species may be treated with the present disclosure. Although one of the objectives or fields of application of thepresent disclosure is its utilization for the manufacture of medicaments for use in the treatment of human beings, the scope and practical utilization of the present disclosure are not limited solely to this species, as demonstrated by its successful use in canines described in this specification.NON-PATENT REFERENCES
[0536] BROWN, Dorothy Cimino; BOSTON, Raymond; COYNE, James C.; FARRAR, John T. A novel approach to the use of animals in studies of pain: validation of the Canine Brief Pain Inventory in canine bone cancer. Pain Medicine, v. 10, n. 1, p. 133-142, 2009.
[0537] BUTCHER, Suzanne K.; O’CARROLL, Christine E.; WELLS, Christine A.; CARMODY, Ruaidhri J. Toll-like receptors drive specific patterns of tolerance and training on restimulation of macrophages. Frontiers in Immunology, v. 9, art.933, 2018.
[0538] CAMPBELL, Jamie; LOWE, David; SLEEMAN, Matthew A. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. British Journal of Pharmacology, v. 162, p. 1470-1484, 2011.
[0539] COLLINS, Patricia E.; CARMODY, Ruaidhri J. The regulation of endotoxin tolerance and its impact on macrophage activation. Critical Reviews in Immunology, v. 35, n. 4, p. 293-324, 2015.
[0540] DEEB, Mery; MAHER, Lewena. Psoriatic arthritis. In: StatPearls [Internet], Treasure Island, FL: StatPearls Publishing, 2026.
[0541] EPSTEIN, Mark E. Osteoarthritis in dogs and cats (osteoarthrosis, degenerative joint disease). In: MSD Veterinary Manual. Rahway, NJ: Merck & Co., 2025.
[0542] FAVARO, Wagner J.; NUNES, Odilon S.; SEIVA, Fabio R. F.; NUNES, Iseu S.; WOOLHISER, Lisa K.; DURAN, Nelson; LENAERTS, Anne J. Effects of P-MAPA immunomodulator on toll-like receptors and p53: potential therapeuticstrategies for infectious diseases and cancer. Infectious Agents and Cancer, v. 7, art. 14, 2012.
[0543] FERGUSON, Duncan. Drug action in animals: pharmacodynamics. In: Merck Veterinary Manual. Rahway, NJ: Merck & Co., 2024.
[0544] GLADMAN, D. D.; ANTONI, C.; MEASE, P.; CLEGG, D.; NASH, P.Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases, v. 64, supl. 2, p. ii 14-ii 17, 2005.
[0545] HUANG, Qi-Quan; POPE, Richard M. The role of toll-like receptors in rheumatoid arthritis. Current Rheumatology Reports, v. 11, n. 5, p. 357-364, 2009.
[0546] JOHNS HOPKINS ARTHRITIS CENTER. Rheumatoid arthritis treatment. Baltimore: Johns Hopkins Medicine, 2025.
[0547] KANG, Eun Jin; KAVANAUGH, Arthur. Psoriatic arthritis: latest treatments and their place in therapy. Therapeutic Advances in Chronic Disease, v. 6, n. 4, p. 194-203, 2015.
[0548] MEDVEDEV, Andrei E.; KOPYDLOWSKI, Karen M.; VOGEL, Stefame N.Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and Tolllike receptor 2 and 4 gene expression. The Journal of Immunology, v. 164, n. 11, p. 5564-5574, 2000.
[0549] MELO, L. M.; PEROSSO, J.; ALMEIDA, B. F. M.; SILVA, K. L. O.; SOMENZARI, M. A.; LIMA, V. M. F. de. Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis. International Immunopharmacology, v. 18, n. 2, p. 373-378, 2014.
[0550] MOLNAR, Vilim et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. International Journal of Molecular Sciences, v. 22, n. 17, art. 9208, 2021.
[0551] SALGUERO, Francisco J.; GARCIA- JIMENEZ, Waldo L.; LIMA, Isadora; SEIFERT, Karin. Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB / c mice: a timecourse study. Parasites & Vectors, v. 11, art. 73, 2018.
[0552] SANT’ANA, J. A. P.; LIMA, W. G.; OLIVEIRA, M. R.; SIMOES, L. A.; MICHALICK, M. S. M.; MELO, M. N.; TAFURI, W. L.; TAFURI, W. G. L. Hepatic granulomas in canine visceral leishmaniasis and clinical status. Arquivo Brasileiro de Medicina Veterindria e Zootecnia, v. 59, n. 5, p. 1137-1144, 2007.
[0553] SANTIAGO, Maria Emilia B.; SILVEIRA NETO, Luiz; ALEXANDRE, Eduardo Costa; MUNARI, Danisio Prado; ANDRADE, Mariana Macedo C.; SOMENZARI, Marcos Arruda; CIARLINI, Paulo Cesar; LIMA, Valeria Manual Felix de. Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA. Acta Tropica, v. 127, n. 3, p. 174-180, 2013.
[0554] SCHNITZER, Thomas J. et al. Opioid prescribing for osteoarthritis: cross-sectional survey among primary care physicians, rheumatologists, and orthopaedic surgeons. Journal of Clinical Medicine, v. 12, n. 2, art. 589, 2023.
[0555] SHARUN, Khan; BANU, Shajahan Amitha; MELOTTI, Luca. Bridging the translational gap: prioritizing the spontaneous canine osteoarthritis model for preclinical studies. Discovery Medicine, v. 37, n. 197, p. 1139-1142, 2025.
[0556] SILVA, Juliana C. S. et al. In vitro and in vivo effects of P-MAPA immunomodulator on schistosomiasis. Acta Tropica, v. 218, art. 105909, 2021.
[0557] SINGH, Jasvinder A.; CLEVELAND, John D. Time trends in opioid use disorder hospitalizations in gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, and low back pain. The Journal of Rheumatology, v. 48, n. 5, p. 775-784, 2021.
[0558] STEINMETZ, Jaimie D. et al. Global, regional, and national burden of osteoarthritis, 1990-2020, and projections to 2050: a systematic analysis for theGlobal Burden of Disease Study 2021. The Lancet Rheumatology, v. 5, n. 9, p. e508-e522, 2023.
[0559] UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA).Freedom of Information Summary: NADA 141-562, Librela™ (bedinvetmab injection). Silver Spring, MD: FDA, 2023.
[0560] UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA).Osteoarthritis in cats: more common than you think. Silver Spring, MD: FDA, 2025.
[0561] WANG, S. X. et al. The economic burden of osteoarthritis in Americans: analysis from a privately insured population. Osteoarthritis and Cartilage, v. 22, supl. 1, 2014.
[0562] ZHANG, Yuqing; JORDAN, Joanne M. Epidemiology of osteoarthritis.Clinics in Geriatric Medicine, v. 26, n. 3, p. 355-369, 2010. DOI: 10.1016 / j.cger.2010.03.001.
Claims
CLAIMSWhat is claimed is:
1. A pharmaceutical composition comprising a polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium and a pharmaceutically acceptable excipient.
2. The pharmaceutical composition of claim 1, wherein the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium comprises 11.6 ± 4.0% of total lipids, being 22.7 ± 5.0% of palmitoleic acid, 42.9 ± 2.0% of linoleic acid, and 32.0 ± 3.0% of oxidized linoleic acid, 20.1 ± 0.9% of magnesium ions, 10.0 ± 3.3% of ammonium ions, 45.2 ± 2.7% of phosphate, and 0.49 ± 0.01% of protein.
3. The pharmaceutical composition of claim 2, wherein the protein of the compound comprises Asp 7.19%, Thr 3.56%, Ser 7.56%, Glu 8.53%, Pro 0.5%, Gly 9.69%, Ala 7.46%, Vai 1.0%, Met 4.38%, He 2.54%, Leu 3.03%, Tyr 0.5%, Phe 1.0%, His 2.83%, Lys 3.56%, Trp 1.3%, and Arg 35.2%.
4. The pharmaceutical composition of claim 1, wherein the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium has an empirical formula C326H614O163N204S2 and a molecular weight of approximately 320,000 Da.
5. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient is sterile 0.9% sodium chloride.
6. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient comprises sodium chloride, dibasic sodium phosphate, monobasic sodium phosphate, water for injection, and physiological saline (0.9% NaCl).
7. The pharmaceutical composition of claim 1, wherein it is formulated for oral administration.
8. The pharmaceutical composition of claim 1, wherein it is formulated for injectable administration.
9. The pharmaceutical composition of claim 8, wherein it comprises at least 25 mg of the polymeric anhydride in a sterile aqueous solution with pharmaceutically acceptable excipients for administration by subcutaneous or intramuscular route.
10. The pharmaceutical composition of claim 1, wherein it is formulated as a controlled-release composition.
11. A unit dosage form com prising from 10 mg to 40 mg of a polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium and a pharmaceutically acceptable excipient, formulated for subcutaneous or intramuscular injection.
12. The unit dosage form of claim 11, comprising 25 mg of the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium.
13. A kit comprising the pharmaceutical composition of any one of claims 1 to 10 and instructions for administering the composition once a week for the treatment of a joint disease selected from osteoarthritis, psoriatic arthritis, rheumatoid arthritis, gouty arthritis, infectious arthritis, idiopathic arthritis, arthrosis, and other inflammatory joint diseases.
14. A method of treating or managing a joint disease selected from osteoarthritis, psoriatic arthritis, rheumatoid arthritis, gouty arthritis, infectious arthritis, idiopathic arthritis, arthrosis, and other inflammatory joint diseases in a human subject, the method comprising administering to the human subject a therapeutically effective amount of a polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium.
15. The method of claim 14, wherein the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium comprises 11.6 ± 4.0% of total lipids, being 22.7 ± 5.0% of palmitoleic acid, 42.9 ± 2.0% of linoleic acid, and 32.0 ± 3.0% of oxidized linoleic acid, 20.1 ± 0.9% of magnesium ions, 10.0 ± 3.3% of ammonium ions, 45.2 ± 2.7% of phosphate, and 0.49 ± 0.01% of protein.
16. The method of claim 15, wherein the protein of the compound comprises Asp 7.19%, Thr 3.56%, Ser 7.56%, Glu 8.53%, Pro 0.5%, Gly 9.69%, Ala 7.46%, Vai 1.0%, Met 4.38%, He 2.54%, Leu 3.03%, Tyr 0.5%, Phe 1.0%, His 2.83%, Lys 3.56%, Trp 1.3%, and Arg 35.2%.
17. The method of claim 14, wherein the polymeric anhydride is administered orally or by injection.
18. The method of claim 14, wherein at least 25 mg of polymeric anhydride is administered by subcutaneous or intramuscular route once a week.
19. The method of claim 14, wherein the joint disease is osteoarthritis.
20. The method of claim 14, wherein the joint disease is rheumatoid arthritis.
21. The method of claim 14, wherein the joint disease is psoriatic arthritis.
22. The method of claim 14, wherein the joint disease is idiopathic arthritis.
23. The method of claim 14, comprising the steps of: performing a clinical evaluation of the human subject including medical history and clinical, laboratory, and radiographic examination; administering at least 25 mg of the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium by intramuscular route once a week; monitoring the therapeutic response through validated scales of pain and quality of life; and continuing the treatment based on the individual clinical response.
24. The method of claim 23, further comprising the steps of: identifying a human subject in whom a prior medicament for the treatment of said joint disease has failed or has produced effects preventing its continued use; discontinuing said prior medicament; and administering the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium in substitution for said prior medicament.
25. The method of claim 24, wherein the prior medicament that is discontinued and substituted belongs to the class of disease-modifying antirheumatic drugs (DMARDs).
26. The method of claim 24, wherein the prior medicament that is discontinued and substituted is methotrexate.
27. The method of claim 24, wherein the prior medicament that is discontinued and substituted belongs to the class of non-steroidal medicaments.
28. The method of claim 24, wherein the prior medicament that is discontinued and substituted is meloxicam.
29. The method of claim 24, wherein the prior medicament that is discontinued and substituted belongs to the class of opioid medicaments.
30. The method of claim 24, wherein the prior medicament that is discontinued and substituted is fentanyl.
31. The method of claim 24, wherein the prior medicament that is discontinued and substituted is oxycodone.
32. The method of claim 24, wherein the prior medicament that is discontinued and substituted is codeine.
33. A method of treating or managing a joint disease selected from osteoarthritis, psoriatic arthritis, rheumatoid arthritis, gouty arthritis, infectious arthritis, idiopathic arthritis, arthrosis, and other inflammatory joint diseases in a non-human animal subject, the method comprising administering to the non-human animal subject a therapeutically effective amount of a polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium.
34. The method of claim 33, wherein the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium comprises 11.6 ± 4.0% of total lipids, being 22.7 ± 5.0% of palmitoleic acid, 42.9 ± 2.0% of linoleic acid, and 32.0 ± 3.0% of oxidized linoleic acid, 20.1 ± 0.9% of magnesium ions, 10.0 ± 3.3% of ammonium ions, 45.2 ± 2.7% of phosphate, and 0.49 ± 0.01% of protein.
35. The method of claim 33, wherein the non-human animal subject is a dog.
36. The method of claim 33, wherein the joint disease is osteoarthritis or arthrosis.
37. The method of claim 33, wherein at least 25 mg of polymeric anhydride is administered by subcutaneous route once a week.
38. The method of claim 33, comprising the steps of performing a veterinary evaluation of the non-human animal subject including clinical, laboratory, and radiographic examination; administering at least 25 mg of the polymeric anhydride of magnesium phospholinoleate-palmitoleate and protein ammonium by subcutaneous route once a week; monitoring the therapeutic response through validated scales of pain and quality of life; and continuing the treatment based on the individual clinical response.
